| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:EML4_ALK |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: EML4_ALK | KinaseFusionDB ID: KFG1964 | FusionGDB2.0 ID: KFG1964 | Hgene | Tgene | Gene symbol | EML4 | ALK | Gene ID | 27436 | 238 | |
| Gene name | EMAP like 4 | ALK receptor tyrosine kinase | ||||||||||
| Synonyms | C2orf2|ELP120|EMAP-4|EMAPL4|ROPP120 | ALK1|CD246|NBLST3 | ||||||||||
| Cytomap | 2p21 | 2p23.2-p23.1 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | echinoderm microtubule-associated protein-like 4echinoderm microtubule associated protein like 4restrictedly overexpressed proliferation-associated proteinropp 120 | ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase | ||||||||||
| Modification date | 20240411 | 20240411 | ||||||||||
| UniProtAcc | Q9HC35 | Q3KRA9 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000318522, ENST00000401738, ENST00000402711, ENST00000453191, ENST00000482660, | ENST00000389048, ENST00000431873, ENST00000498037, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: EML4 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract] Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer (pmid: 17625570) | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | EML4(42552694)-ALK(29446394), # samples:6 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ALK | GO:0007169 | cell surface receptor protein tyrosine kinase signaling pathway | 25605972|30061385|34646012 |
| Tgene | ALK | GO:0016310 | phosphorylation | 9174053 |
| Tgene | ALK | GO:0038083 | peptidyl-tyrosine autophosphorylation | 30061385|34646012 |
| Tgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
| Tgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
| Kinase Fusion gene breakpoints across EML4 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Kinase Fusion gene breakpoints across ALK (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerKB3 | . | EML4 | chr2 | 42522657 | ALK | chr2 | 29416041 |
| ChimerKB3 | . | EML4 | chr2 | 42492091 | ALK | chr2 | 29416042 |
| ChimerDB4 | AB274722 | EML4 | chr2 | 42522660 | ALK | chr2 | 29415644 |
| ChimerKB3 | . | EML4 | chr2 | 42483770 | ALK | chr2 | 29415644 |
| ChiTaRS5.0 | AB374365 | EML4 | chr2 | 42472829 | ALK | chr2 | 29446515 |
| ChiTaRS5.0 | AB462411 | EML4 | chr2 | 42522657 | ALK | chr2 | 29446465 |
| ChiTaRS5.0 | GU797894 | EML4 | chr2 | 42531692 | ALK | chr2 | 29446427 |
| ChiTaRS5.0 | JQ828841 | EML4 | chr2 | 42483770 | ALK | chr2 | 29446449 |
| ChimerDB4 | TCGA-2Z-A9JJ-01A | EML4 | chr2 | 42472827 | ALK | chr2 | 29446394 |
| ChimerDB4 | TCGA-67-6215-01A | EML4 | chr2 | 42491871 | ALK | chr2 | 29446394 |
| ChimerDB4 | TCGA-67-6216-01A | EML4 | chr2 | 42491870 | ALK | chr2 | 29446393 |
| ChimerDB4 | TCGA-78-7163-01A | EML4 | chr2 | 42522655 | ALK | chr2 | 29446393 |
| ChimerDB4 | TCGA-78-7163-01A | EML4 | chr2 | 42522656 | ALK | chr2 | 29446394 |
| ChimerDB4 | TCGA-86-A4P8-01A | EML4 | chr2 | 42552694 | ALK | chr2 | 29446394 |
| ChimerDB4 | TCGA-E8-A432-01A | EML4 | chr2 | 42491871 | ALK | chr2 | 29449940 |
| ChimerDB4 | TCGA-E8-A432-01A | EML4 | chr2 | 42491871 | ALK | chr2 | 29450538 |
| ChimerKB3 | . | EML4 | chr2 | 42483770 | ALK | chr2 | 29446319 |
| ChimerKB3 | . | EML4 | chr2 | 42491870 | ALK | chr2 | 29446393 |
| ChimerKB3 | . | EML4 | chr2 | 42491871 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42522655 | ALK | chr2 | 29416090 |
| ChimerKB3 | . | EML4 | chr2 | 42522656 | ALK | chr2 | 29443701 |
| ChimerKB3 | . | EML4 | chr2 | 42522656 | ALK | chr2 | 29445473 |
| ChimerKB3 | . | EML4 | chr2 | 42522656 | ALK | chr2 | 29446393 |
| ChimerKB3 | . | EML4 | chr2 | 42522656 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42522657 | ALK | chr2 | 29445266 |
| ChimerKB3 | . | EML4 | chr2 | 42522660 | ALK | chr2 | 29446319 |
| ChimerKB3 | . | EML4 | chr2 | 42528532 | ALK | chr2 | 29445266 |
| ChimerKB3 | . | EML4 | chr2 | 42528532 | ALK | chr2 | 29446319 |
| ChimerKB3 | . | EML4 | chr2 | 42531692 | ALK | chr2 | 29446319 |
| ChimerKB3 | . | EML4 | chr2 | 42531692 | ALK | chr2 | 29446393 |
| ChimerKB3 | . | EML4 | chr2 | 42552694 | ALK | chr2 | 29416090 |
| ChimerKB3 | . | EML4 | chr2 | 42552694 | ALK | chr2 | 29445266 |
| ChimerKB3 | . | EML4 | chr2 | 42552694 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42552694 | ALK | chr2 | 29449940 |
| ChimerKB3 | . | EML4 | chr2 | 42553392 | ALK | chr2 | 29446394 |
| ChiTaRS5.0 | AB274722 | EML4 | chr2 | 42522660 | ALK | chr2 | 29446396 |
| ChiTaRS5.0 | AB275889 | EML4 | chr2 | 42552694 | ALK | chr2 | 29446394 |
| ChiTaRS5.0 | AB374361 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446396 |
| ChiTaRS5.0 | AB374364 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446396 |
| ChiTaRS5.0 | AB462412 | EML4 | chr2 | 42528532 | ALK | chr2 | 29446382 |
| ChimerKB3 | . | EML4 | chr2 | 42492091 | ALK | chr2 | 29415644 |
| ChimerDB4 | TCGA-50-8460-01A | EML4 | chr2 | 42492090 | ALK | chr2 | 29446393 |
| ChimerDB4 | TCGA-50-8460-01A | EML4 | chr2 | 42492091 | ALK | chr2 | 29446394 |
| ChimerDB4 | TCGA-E8-A432-01A | EML4 | chr2 | 42492091 | ALK | chr2 | 29449940 |
| ChimerDB4 | TCGA-E8-A432-01A | EML4 | chr2 | 42492091 | ALK | chr2 | 29450538 |
| ChimerKB3 | . | EML4 | chr2 | 42492090 | ALK | chr2 | 29446393 |
| ChimerKB3 | . | EML4 | chr2 | 42492091 | ALK | chr2 | 29445266 |
| ChimerKB3 | . | EML4 | chr2 | 42492091 | ALK | chr2 | 29446394 |
| ChiTaRS5.0 | AB374362 | EML4 | chr2 | 42492091 | ALK | chr2 | 29446396 |
| ChimerKB3 | . | EML4 | chr2 | 42472644 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42526287 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42532902 | ALK | chr2 | 29446394 |
| ChimerKB3 | . | EML4 | chr2 | 42345595 | ALK | chr2 | 29269593 |
| ChimerKB3 | . | EML4 | chr2 | 42376164 | ALK | chr2 | 29269148 |
| ChimerKB3 | . | EML4 | chr2 | 42406198 | ALK | chr2 | 29269148 |
| ChiTaRS5.0 | GU797895 | EML4 | chr2 | 42532902 | ALK | chr2 | 29446432 |
| COSMIC | 1081879 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446691 |
| COSMIC | 1107461 | EML4 | chr2 | 42525231 | ALK | chr2 | 29446597 |
| COSMIC | 1146764 | EML4 | chr2 | 42553239 | ALK | chr2 | 29446626 |
| COSMIC | 1146766 | EML4 | chr2 | 42524141 | ALK | chr2 | 29447648 |
| COSMIC | 1146959 | EML4 | chr2 | 42530369 | ALK | chr2 | 29446394 |
| COSMIC | 1146960 | EML4 | chr2 | 42530369 | ALK | chr2 | 29446394 |
| COSMIC | 1166407 | EML4 | chr2 | 42528532 | ALK | chr2 | 29446345 |
| COSMIC | 1166408 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446511 |
| COSMIC | 1177255 | EML4 | chr2 | 42552876 | ALK | chr2 | 29446461 |
| COSMIC | 1177256 | EML4 | chr2 | 42543844 | ALK | chr2 | 29446566 |
| COSMIC | 1177257 | EML4 | chr2 | 42492676 | ALK | chr2 | 29446509 |
| COSMIC | 1177260 | EML4 | chr2 | 42523103 | ALK | chr2 | 29446555 |
| COSMIC | 1214899 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446463 |
| COSMIC | 1214904 | EML4 | chr2 | 42528532 | ALK | chr2 | 29446394 |
| COSMIC | 1305536 | EML4 | chr2 | 42552694 | ALK | chr2 | 29446412 |
| COSMIC | 1305537 | EML4 | chr2 | 42531691 | ALK | chr2 | 29446394 |
| COSMIC | 1436077 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446511 |
| COSMIC | 1436078 | EML4 | chr2 | 42543844 | ALK | chr2 | 29446566 |
| COSMIC | 1436079 | EML4 | chr2 | 42543844 | ALK | chr2 | 29446566 |
| COSMIC | 1436080 | EML4 | chr2 | 42543844 | ALK | chr2 | 29446566 |
| COSMIC | 1548834 | EML4 | chr2 | 42528532 | ALK | chr2 | 29446394 |
| COSMIC | 1705460 | EML4 | chr2 | 42491871 | ALK | chr2 | 29448431 |
| COSMIC | 1822547 | EML4 | chr2 | 42534213 | ALK | chr2 | 29446348 |
| COSMIC | 1843317 | EML4 | chr2 | 42543190 | ALK | chr2 | 29446394 |
| COSMIC | 1843318 | EML4 | chr2 | 42543190 | ALK | chr2 | 29446394 |
| COSMIC | 2081996 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446484 |
| COSMIC | 2082006 | EML4 | chr2 | 42528532 | ALK | chr2 | 29446517 |
| COSMIC | 2085493 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446412 |
| COSMIC | 2085494 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446412 |
| COSMIC | 2522066 | EML4 | chr2 | 42543190 | ALK | chr2 | 29446394 |
| CCLE | HS-PSS | EML4 | chr2 | 42472827 | ALK | chr2 | 29447544 |
| CCLE | SNU-324 | EML4 | chr2 | 42492091 | ALK | chr2 | 29447544 |
| CCLE | SNU-324 | EML4 | chr2 | 42491871 | ALK | chr2 | 29447544 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29448431 | 3175 | 820 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42543190 | ALK | chr2 | 29446394 | 4459 | 1248 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446394 | 2611 | 632 |
| ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29446394 | 2992 | 796 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446394 | 3070 | 785 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446394 | 3892 | 1059 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42552694 | ALK | chr2 | 29446394 | 4645 | 1310 |
| ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29449940 | 3250 | 882 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29449940 | 3328 | 871 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29450538 | 3427 | 904 |
| ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29450538 | 3349 | 915 |
| ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492090 | ALK | chr2 | 29446393 | 2992 | 796 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491870 | ALK | chr2 | 29446393 | 3070 | 785 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522655 | ALK | chr2 | 29446393 | 3892 | 1059 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522660 | ALK | chr2 | 29446396 | 3892 | 1059 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446396 | 3070 | 785 |
| ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29446396 | 2992 | 796 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446396 | 2611 | 632 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446393 | 3892 | 1059 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522660 | ALK | chr2 | 29446319 | 3817 | 526 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42528532 | ALK | chr2 | 29445266 | 3758 | 779 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42552694 | ALK | chr2 | 29449940 | 4903 | 1396 |
| ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42553392 | ALK | chr2 | 29446394 | 4744 | 1343 |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq >ENST00000318522_ENST00000389048_EML4_chr2_42491871_ALK_chr2_29448431_length(amino acids)=820 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQ MELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQD ELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDI AARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLE FVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQA KREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNN PIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILK -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42543190_ALK_chr2_29446394_length(amino acids)=1248 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDY NPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRC IGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFG MARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIM TQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKA AKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42472827_ALK_chr2_29446394_length(amino acids)=632 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKVYRRKHQELQAMQMELQSPEY KLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEA LIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLT CPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRM DPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSP AAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPH DRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQP -------------------------------------------------------------- >ENST00000401738_ENST00000389048_EML4_chr2_42492091_ALK_chr2_29446394_length(amino acids)=796 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42491871_ALK_chr2_29446394_length(amino acids)=785 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42522656_ALK_chr2_29446394_length(amino acids)=1059 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42552694_ALK_chr2_29446394_length(amino acids)=1310 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYLYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIR GLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRE TRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEA FMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDP DVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAF SQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVP -------------------------------------------------------------- >ENST00000401738_ENST00000389048_EML4_chr2_42492091_ALK_chr2_29449940_length(amino acids)=882 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFC DHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCF AGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQ SLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIY RASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQH QPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTA AEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATG -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42491871_ALK_chr2_29449940_length(amino acids)=871 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGV SCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLK EVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELM AGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCA MLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAII LERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42491871_ALK_chr2_29450538_length(amino acids)=904 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLN CSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSP EYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLM EALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCL LTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGG RMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEER SPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKE PHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMN -------------------------------------------------------------- >ENST00000401738_ENST00000389048_EML4_chr2_42492091_ALK_chr2_29450538_length(amino acids)=915 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEG HGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQE LQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEV CSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHF IHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSN QEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLL VSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKP TKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYE -------------------------------------------------------------- >ENST00000401738_ENST00000389048_EML4_chr2_42492090_ALK_chr2_29446393_length(amino acids)=796 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42491870_ALK_chr2_29446393_length(amino acids)=785 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42522655_ALK_chr2_29446393_length(amino acids)=1059 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42522660_ALK_chr2_29446396_length(amino acids)=1059 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42491871_ALK_chr2_29446396_length(amino acids)=785 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL -------------------------------------------------------------- >ENST00000401738_ENST00000389048_EML4_chr2_42492091_ALK_chr2_29446396_length(amino acids)=796 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42472827_ALK_chr2_29446396_length(amino acids)=632 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKVYRRKHQELQAMQMELQSPEY KLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEA LIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLT CPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRM DPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSP AAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPH DRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42522656_ALK_chr2_29446393_length(amino acids)=1059 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42522660_ALK_chr2_29446319_length(amino acids)=526 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42528532_ALK_chr2_29445266_length(amino acids)=779 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAV EGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSS -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42552694_ALK_chr2_29449940_length(amino acids)=1396 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYLMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLS LILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGH GAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPR PSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEG IFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVIN TALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSN PPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRL -------------------------------------------------------------- >ENST00000318522_ENST00000389048_EML4_chr2_42553392_ALK_chr2_29446394_length(amino acids)=1343 MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYWDIPNGCKLIRNRSDCKDIDWTTYTCVLGFQVFVYRRKHQELQAMQMELQSPEYKLSKLRTST IMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQ NIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAK IGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGP VYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTT SSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEG -------------------------------------------------------------- |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:42552694/chr2:29446394) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| EML4 | ALK |
| FUNCTION: Essential for the formation and stability of microtubules (MTs) (PubMed:16890222, PubMed:31409757). Required for the organization of the mitotic spindle and for the proper attachment of kinetochores to MTs (PubMed:25789526). Promotes the recruitment of NUDC to the mitotic spindle for mitotic progression (PubMed:25789526). {ECO:0000269|PubMed:16890222, ECO:0000269|PubMed:25789526, ECO:0000269|PubMed:31409757}. | FUNCTION: Probable dioxygenase that requires molecular oxygen, alpha-ketoglutarate and iron. {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| Tgene | EML4 | 42522660 | ALK | 29446319 | ENST00000318522 | 0 | 29 | 437_473 | 0 | 1621 | Domain | Note=LDL-receptor class A |
| Tgene | EML4 | 42528532 | ALK | 29445266 | ENST00000318522 | 0 | 29 | 437_473 | 0 | 1621 | Domain | Note=LDL-receptor class A |
| Tgene | EML4 | 42522660 | ALK | 29446319 | ENST00000318522 | 0 | 29 | 264_427 | 0 | 1621 | Domain | Note=MAM 1;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128 |
| Tgene | EML4 | 42528532 | ALK | 29445266 | ENST00000318522 | 0 | 29 | 264_427 | 0 | 1621 | Domain | Note=MAM 1;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128 |
| Tgene | EML4 | 42522660 | ALK | 29446319 | ENST00000318522 | 0 | 29 | 478_636 | 0 | 1621 | Domain | Note=MAM 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128 |
| Tgene | EML4 | 42528532 | ALK | 29445266 | ENST00000318522 | 0 | 29 | 478_636 | 0 | 1621 | Domain | Note=MAM 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128 |
| Tgene | EML4 | 42472827 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42472827 | ALK | 29446396 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491870 | ALK | 29446393 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491871 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491871 | ALK | 29446396 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491871 | ALK | 29448431 | ENST00000318522 | 17 | 29 | 1116_1392 | 1022 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491871 | ALK | 29449940 | ENST00000318522 | 16 | 29 | 1116_1392 | 971 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42491871 | ALK | 29450538 | ENST00000318522 | 15 | 29 | 1116_1392 | 938 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42492090 | ALK | 29446393 | ENST00000401738 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42492091 | ALK | 29446394 | ENST00000401738 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42492091 | ALK | 29446396 | ENST00000401738 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42492091 | ALK | 29449940 | ENST00000401738 | 16 | 29 | 1116_1392 | 971 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42492091 | ALK | 29450538 | ENST00000401738 | 15 | 29 | 1116_1392 | 938 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42522655 | ALK | 29446393 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42522656 | ALK | 29446393 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42522656 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42522660 | ALK | 29446319 | ENST00000318522 | 0 | 29 | 1116_1392 | 0 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42522660 | ALK | 29446396 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42528532 | ALK | 29445266 | ENST00000318522 | 0 | 29 | 1116_1392 | 0 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42543190 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42552694 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42552694 | ALK | 29449940 | ENST00000318522 | 16 | 29 | 1116_1392 | 971 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | EML4 | 42553392 | ALK | 29446394 | ENST00000318522 | 18 | 29 | 1116_1392 | 1057 | 1621 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
Top |
Kinase Fusion Protein Structures |
| CIF files of the predicted kinase fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB) | Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | AA seq | Len(AA seq) |
| PDB file >>>160_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42553392 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYWDIPNGCKLIRNRSDCKDIDWTTYTCVLGFQVFVYRRKHQELQAMQMELQSPEYKLSKLRTST IMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQ NIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAK IGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGP VYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTT SSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEG | 1343 |
| 3D view using mol* of 160_EML4_ALK | ||||||||||
| PDB file >>>TKFP_255_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29448431 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQ MELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQD ELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDI AARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLE FVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQA KREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNN PIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILK | 820_EML4_ALK |
| PDB file >>>TKFP_256_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42543190 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDY NPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRC IGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFG MARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIM TQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKA AKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVP | 1248_EML4_ALK |
| 3D view using mol* of TKFP_256_EML4_ALK | ||||||||||
| PDB file >>>TKFP_257_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKVYRRKHQELQAMQMELQSPEY KLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEA LIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLT CPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRM DPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSP AAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPH DRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQP | 632_EML4_ALK |
| 3D view using mol* of TKFP_257_EML4_ALK | ||||||||||
| PDB file >>>TKFP_258_EML4_ALK | ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN | 796_EML4_ALK |
| 3D view using mol* of TKFP_258_EML4_ALK | ||||||||||
| PDB file >>>TKFP_259_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL | 785_EML4_ALK |
| 3D view using mol* of TKFP_259_EML4_ALK | ||||||||||
| PDB file >>>TKFP_260_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP | 1059_EML4_ALK |
| 3D view using mol* of TKFP_260_EML4_ALK | ||||||||||
| PDB file >>>TKFP_261_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42552694 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYLYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIR GLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRE TRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEA FMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDP DVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAF SQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVP | 1310_EML4_ALK |
| 3D view using mol* of TKFP_261_EML4_ALK | ||||||||||
| PDB file >>>TKFP_262_EML4_ALK | ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29449940 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFC DHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCF AGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQ SLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIY RASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQH QPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTA AEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATG | 882_EML4_ALK |
| 3D view using mol* of TKFP_262_EML4_ALK | ||||||||||
| PDB file >>>TKFP_263_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29449940 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGV SCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLK EVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELM AGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCA MLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAII LERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP | 871_EML4_ALK |
| 3D view using mol* of TKFP_263_EML4_ALK | ||||||||||
| PDB file >>>TKFP_264_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29450538 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLN CSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSP EYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLM EALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCL LTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGG RMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEER SPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKE PHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMN | 904_EML4_ALK |
| 3D view using mol* of TKFP_264_EML4_ALK | ||||||||||
| PDB file >>>TKFP_265_EML4_ALK | ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29450538 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEG HGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQE LQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEV CSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHF IHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSN QEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLL VSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKP TKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYE | 915_EML4_ALK |
| 3D view using mol* of TKFP_265_EML4_ALK | ||||||||||
| PDB file >>>TKFP_266_EML4_ALK | ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492090 | ALK | chr2 | 29446393 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN | 796_EML4_ALK |
| PDB file >>>TKFP_267_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491870 | ALK | chr2 | 29446393 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL | 785_EML4_ALK |
| PDB file >>>TKFP_268_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522655 | ALK | chr2 | 29446393 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP | 1059_EML4_ALK |
| PDB file >>>TKFP_269_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522660 | ALK | chr2 | 29446396 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP | 1059_EML4_ALK |
| PDB file >>>TKFP_270_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42491871 | ALK | chr2 | 29446396 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSI SDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFIL LELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPN FAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRV PRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASL | 785_EML4_ALK |
| PDB file >>>TKFP_271_EML4_ALK | ENST00000401738 | ENST00000389048 | EML4 | chr2 | 42492091 | ALK | chr2 | 29446396 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQAKMSTREKNSQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNP NYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIG VSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMA RDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQ CWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAK KPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPN | 796_EML4_ALK |
| PDB file >>>TKFP_272_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42472827 | ALK | chr2 | 29446396 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKVYRRKHQELQAMQMELQSPEY KLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEA LIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLT CPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRM DPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSP AAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPH DRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQP | 632_EML4_ALK |
| PDB file >>>TKFP_273_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522656 | ALK | chr2 | 29446393 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGK TSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLP RFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAS YYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPE DRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEI SVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLP | 1059_EML4_ALK |
| PDB file >>>TKFP_274_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42522660 | ALK | chr2 | 29446319 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF | 526_EML4_ALK |
| 3D view using mol* of TKFP_274_EML4_ALK | ||||||||||
| PDB file >>>TKFP_275_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42528532 | ALK | chr2 | 29445266 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAV EGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSS | 779_EML4_ALK |
| 3D view using mol* of TKFP_275_EML4_ALK | ||||||||||
| PDB file >>>TKFP_276_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42552694 | ALK | chr2 | 29449940 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYLMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLS LILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGH GAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPR PSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEG IFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVIN TALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSN PPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRL | 1396_EML4_ALK |
| 3D view using mol* of TKFP_276_EML4_ALK | ||||||||||
| PDB file >>>TKFP_277_EML4_ALK | ENST00000318522 | ENST00000389048 | EML4 | chr2 | 42553392 | ALK | chr2 | 29446394 | MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGAN RKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEK SHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGK DCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLG TFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIF GKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDL NPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTR LVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGH SSYITHLDWSPDNKYIMSNSGDYEILYWDIPNGCKLIRNRSDCKDIDWTTYTCVLGFQVFVYRRKHQELQAMQMELQSPEYKLSKLRTST IMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQ NIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAK IGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGP VYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTT SSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEG | 1343_EML4_ALK |
| 3D view using mol* of TKFP_277_EML4_ALK | ||||||||||
Top |
Comparison of Fusion Protein Isoforms |
| Superimpose the 3D Structures Among All Fusion Protein Isoforms * Download the pdb file and open it from the molstar online viewer. |
| Comparison of the Secondary Structures of Fusion Protein Isoforms |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_255_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_256_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_256_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_256_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_256_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_256_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_255_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_274_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_257_EML4_ALK_vs_TKFP_277_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_258_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_260_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_260_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_260_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_260_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_261_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_261_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_261_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_255_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_257_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_274_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_275_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_263_EML4_ALK_vs_TKFP_277_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_264_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_265_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_265_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_255_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_274_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_255_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_257_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_274_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
| ./secondary_str/TKFP_275_EML4_ALK_vs_TKFP_277_EML4_ALK.png |
 |
| ./secondary_str/TKFP_276_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_255_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_256_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_258_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_259_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_260_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_261_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_264_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_265_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_274_EML4_ALK.png |
 |
| ./secondary_str/TKFP_277_EML4_ALK_vs_TKFP_276_EML4_ALK.png |
 |
Top |
Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB |
Abstract of the Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names  |
| Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names |
| Superimpose the 3D Structures Between the Longest Fusion Protein and the Longest Known PDB |
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. * The blue color at the bottom marks the best active site residues. |
| 160_EML4_ALK.png |
 |
| 160_EML4_ALK.png |
 |
| TKFP_259_EML4_ALK.png |
 |
| TKFP_261_EML4_ALK.png |
 |
| TKFP_262_EML4_ALK.png |
 |
| TKFP_263_EML4_ALK.png |
 |
| TKFP_264_EML4_ALK.png |
 |
| TKFP_265_EML4_ALK.png |
 |
| TKFP_275_EML4_ALK.png |
 |
| TKFP_276_EML4_ALK.png |
 |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Kinase Fusion AA seq ID in KinaseFusionDB | Site score | Size | Dscore | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| TKFP_259_EML4_ALK | 1.072 | 119 | 1.141 | 301.497 | 0.559 | 0.701 | 0.933 | 1.326 | 0.675 | 1.964 | 0.734 | Chain A: 413,438,441,442,444,445,447,448,449,450,4 51,452,453,454,456,457,458,461,466,467,468,469,471 ,504 |
| TKFP_261_EML4_ALK | 1.039 | 372 | 1.08 | 1071.189 | 0.53 | 0.707 | 0.886 | 0.547 | 0.87 | 0.629 | 1.054 | Chain A: 229,231,236,596,597,598,599,600,602,603,6 37,638,639,640,641,642,643,679,680,681,682,683,684 ,685,723,725,726,727,728,729,730,735,736,737,738,7 39,740,741,743,745,747,1261,1262,1263,1264,1265,12 66,1267,1268,1269,1270,1271,1272,1274,1276 |
| TKFP_263_EML4_ALK | 1.027 | 437 | 1.043 | 1326.038 | 0.518 | 0.739 | 0.942 | 0.732 | 1.043 | 0.702 | 0.646 | Chain A: 28,29,30,32,33,36,37,39,40,41,371,373,374 ,375,376,377,378,381,399,401,418,422,431,447,448,4 49,450,451,452,453,454,456,457,460,461,463,498,500 ,504,505,507,520,521,522,523,524,525,526,527,540,5 41,542,543,544,545,546,577,578,579,582,583,584,585 ,586,752,754,755,756,757,758,759,760,761,762,763 |
| TKFP_264_EML4_ALK | 1.034 | 356 | 1.058 | 1106.175 | 0.512 | 0.735 | 0.946 | 0.72 | 0.99 | 0.728 | 0.805 | Chain A: 404,405,406,407,408,409,410,411,413,414,4 32,433,434,451,455,464,480,481,482,483,484,485,486 ,487,490,491,493,494,496,531,533,537,538,540,544,5 53,554,555,556,557,559,574,575,576,577,578,579,612 ,618,619,782,783,784,785,787,788,789,790,791,792,7 93,794,795,796,797,798 |
| TKFP_265_EML4_ALK | 1.028 | 378 | 1.058 | 1047.522 | 0.575 | 0.716 | 0.883 | 0.641 | 0.957 | 0.67 | 0.893 | Chain A: 389,391,392,393,394,395,415,417,418,419,4 20,421,422,425,443,445,454,457,458,461,462,465,475 ,491,492,493,494,495,496,497,498,500,501,502,504,5 05,507,538,539,540,541,542,543,544,548,549,551,564 ,565,566,567,568,569,570,571,572,573,574,575,576,5 77,621,622,623,626,798,800,802,804,805,806,807 |
| TKFP_275_EML4_ALK | 1.03 | 830 | 1.051 | 2758.063 | 0.511 | 0.735 | 0.964 | 0.61 | 1.012 | 0.603 | 0.61 | Chain A: 263,264,265,266,267,268,269,270,271,272,2 73,274,275,276,277,278,279,280,282,284,286,288,289 ,295,296,297,298,300,302,311,313,314,315,316,317,3 18,319,321,367,368,369,370,373,374,375,376,383,385 ,389,411,412,413,414,415,416,419,420,421,422,461,4 62,463,464,465,466,467,468,471,513,514,515,516,517 ,518,519,521,522,523,524,525,526,527,528,529,531,5 32,533,538,540,544,545,546,547,548,549,550,551,632 ,633,634,635,636,637,638,639,664,670,672,673,728,7 29,730,731,732,733,734,735,736,737,738,739,740,741 ,743 |
| TKFP_276_EML4_ALK | 1.052 | 407 | 1.036 | 1169.973 | 0.483 | 0.776 | 0.99 | 0.504 | 1.133 | 0.445 | 0.609 | Chain A: 263,264,265,266,268,270,271,272,273,274,2 75,276,277,278,279,280,282,287,288,289,311,313,314 ,315,316,317,318,319,321,364,367,368,369,370,371,3 73,383,384,385,386,387,389,411,412,413,414,415,416 ,460,461,462,463,464,513,514,515,516,517,518,519,5 56,557,558,559,560,561,562,563,573,590,591,592,593 ,594,595,607,609,617,619,1280,1281,1282 |
| TKFP_262_EML4_ALK | 1.035 | 469 | 1.061 | 1423.107 | 0.547 | 0.733 | 0.929 | 0.682 | 0.979 | 0.697 | 0.712 | Chain A: 29,30,32,33,36,37,39,40,41,43,44,47,50,38 2,383,384,385,386,387,388,389,390,391,392,410,412, 429,433,442,458,459,460,461,462,463,464,465,468,46 9,471,472,473,474,509,511,515,516,518,531,532,533, 534,535,536,537,538,551,552,553,554,555,556,557,58 9,590,593,594,595,596,597,761,762,763,764,765,766, 767,768,769,770,772,773,774 |
| Binding site residues of the found PDBs. |
| PDB accession | AA sequence | Residue position |
| 3AOX | SER | 1086 |
| 3AOX | THR | 1087 |
| 3AOX | ILE | 1088 |
| 3AOX | MET | 1089 |
| 3AOX | THR | 1090 |
| 3AOX | ASP | 1091 |
| 3AOX | TYR | 1092 |
| 3AOX | ASN | 1093 |
| 3AOX | PRO | 1094 |
| 3AOX | ASN | 1095 |
| 3AOX | TYR | 1096 |
| 3AOX | CYS | 1097 |
| 3AOX | PHE | 1098 |
| 3AOX | ALA | 1099 |
| 3AOX | GLY | 1100 |
| 3AOX | LYS | 1101 |
| 3AOX | THR | 1102 |
| 3AOX | SER | 1103 |
| 3AOX | SER | 1104 |
| 3AOX | ILE | 1105 |
| 3AOX | SER | 1106 |
| 3AOX | ASP | 1107 |
| 3AOX | LEU | 1108 |
| 3AOX | LYS | 1109 |
| 3AOX | GLU | 1110 |
| 3AOX | VAL | 1111 |
| 3AOX | PRO | 1112 |
| 3AOX | ARG | 1113 |
| 3AOX | LYS | 1114 |
| 3AOX | ASN | 1115 |
| 3AOX | ILE | 1116 |
| 3AOX | THR | 1117 |
| 3AOX | LEU | 1118 |
| 3AOX | ILE | 1119 |
| 3AOX | ARG | 1120 |
| 3AOX | GLY | 1121 |
| 3AOX | LEU | 1122 |
| 3AOX | GLY | 1123 |
| 3AOX | GLY | 1128 |
| 3AOX | GLU | 1129 |
| 3AOX | VAL | 1130 |
| 3AOX | TYR | 1131 |
| 3AOX | GLU | 1132 |
| 3AOX | GLY | 1133 |
| 3AOX | GLN | 1134 |
| 3AOX | VAL | 1135 |
| 3AOX | SER | 1136 |
| 3AOX | PRO | 1144 |
| 3AOX | LEU | 1145 |
| 3AOX | GLN | 1146 |
| 3AOX | VAL | 1147 |
| 3AOX | ALA | 1148 |
| 3AOX | VAL | 1149 |
| 3AOX | LYS | 1150 |
| 3AOX | THR | 1151 |
| 3AOX | LEU | 1152 |
| 3AOX | PRO | 1153 |
| 3AOX | GLU | 1154 |
| 3AOX | VAL | 1155 |
| 3AOX | CYS | 1156 |
| 3AOX | SER | 1157 |
| 3AOX | GLU | 1158 |
| 3AOX | GLN | 1159 |
| 3AOX | ASP | 1160 |
| 3AOX | GLU | 1161 |
| 3AOX | LEU | 1162 |
| 3AOX | ASP | 1163 |
| 3AOX | PHE | 1164 |
| 3AOX | LEU | 1165 |
| 3AOX | MET | 1166 |
| 3AOX | GLU | 1167 |
| 3AOX | ALA | 1168 |
| 3AOX | LEU | 1169 |
| 3AOX | ILE | 1170 |
| 3AOX | ILE | 1171 |
| 3AOX | SER | 1172 |
| 3AOX | LYS | 1173 |
| 3AOX | PHE | 1174 |
| 3AOX | ASN | 1175 |
| 3AOX | HIS | 1176 |
| 3AOX | GLN | 1177 |
| 3AOX | ASN | 1178 |
| 3AOX | ILE | 1179 |
| 3AOX | VAL | 1180 |
| 3AOX | ARG | 1181 |
| 3AOX | CYS | 1182 |
| 3AOX | ILE | 1183 |
| 3AOX | GLY | 1184 |
| 3AOX | VAL | 1185 |
| 3AOX | SER | 1186 |
| 3AOX | LEU | 1187 |
| 3AOX | GLN | 1188 |
| 3AOX | SER | 1189 |
| 3AOX | LEU | 1190 |
| 3AOX | PRO | 1191 |
| 3AOX | ARG | 1192 |
| 3AOX | PHE | 1193 |
| 3AOX | ILE | 1194 |
| 3AOX | LEU | 1195 |
| 3AOX | LEU | 1196 |
| 3AOX | GLU | 1197 |
| 3AOX | LEU | 1198 |
| 3AOX | MET | 1199 |
| 3AOX | ALA | 1200 |
| 3AOX | GLY | 1201 |
| 3AOX | GLY | 1202 |
| 3AOX | ASP | 1203 |
| 3AOX | LEU | 1204 |
| 3AOX | LYS | 1205 |
| 3AOX | SER | 1206 |
| 3AOX | PHE | 1207 |
| 3AOX | LEU | 1208 |
| 3AOX | ARG | 1209 |
| 3AOX | GLU | 1210 |
| 3AOX | THR | 1211 |
| 3AOX | ARG | 1212 |
| 3AOX | PRO | 1213 |
| 3AOX | ARG | 1214 |
| 3AOX | PRO | 1215 |
| 3AOX | SER | 1216 |
| 3AOX | GLN | 1217 |
| 3AOX | PRO | 1218 |
| 3AOX | SER | 1219 |
| 3AOX | SER | 1220 |
| 3AOX | LEU | 1221 |
| 3AOX | ALA | 1222 |
| 3AOX | MET | 1223 |
| 3AOX | LEU | 1224 |
| 3AOX | ASP | 1225 |
| 3AOX | LEU | 1226 |
| 3AOX | LEU | 1227 |
| 3AOX | HIS | 1228 |
| 3AOX | VAL | 1229 |
| 3AOX | ALA | 1230 |
| 3AOX | ARG | 1231 |
| 3AOX | ASP | 1232 |
| 3AOX | ILE | 1233 |
| 3AOX | ALA | 1234 |
| 3AOX | CYS | 1235 |
| 3AOX | GLY | 1236 |
| 3AOX | CYS | 1237 |
| 3AOX | GLN | 1238 |
| 3AOX | TYR | 1239 |
| 3AOX | LEU | 1240 |
| 3AOX | GLU | 1241 |
| 3AOX | GLU | 1242 |
| 3AOX | ASN | 1243 |
| 3AOX | HIS | 1244 |
| 3AOX | PHE | 1245 |
| 3AOX | ILE | 1246 |
| 3AOX | HIS | 1247 |
| 3AOX | ARG | 1248 |
| 3AOX | ASP | 1249 |
| 3AOX | ILE | 1250 |
| 3AOX | ALA | 1251 |
| 3AOX | ALA | 1252 |
| 3AOX | ARG | 1253 |
| 3AOX | ASN | 1254 |
| 3AOX | CYS | 1255 |
| 3AOX | LEU | 1256 |
| 3AOX | LEU | 1257 |
| 3AOX | THR | 1258 |
| 3AOX | CYS | 1259 |
| 3AOX | PRO | 1260 |
| 3AOX | GLY | 1261 |
| 3AOX | PRO | 1262 |
| 3AOX | GLY | 1263 |
| 3AOX | ARG | 1264 |
| 3AOX | VAL | 1265 |
| 3AOX | ALA | 1266 |
| 3AOX | LYS | 1267 |
| 3AOX | ILE | 1268 |
| 3AOX | GLY | 1269 |
| 3AOX | ASP | 1270 |
| 3AOX | PHE | 1271 |
| 3AOX | GLY | 1272 |
| 3AOX | MET | 1273 |
| 3AOX | ALA | 1274 |
| 3AOX | ARG | 1275 |
| 3AOX | ASP | 1276 |
| 3AOX | ILE | 1277 |
| 3AOX | TYR | 1278 |
| 3AOX | ARG | 1279 |
| 3AOX | ALA | 1280 |
| 3AOX | CYS | 1288 |
| 3AOX | ALA | 1289 |
| 3AOX | MET | 1290 |
| 3AOX | LEU | 1291 |
| 3AOX | PRO | 1292 |
| 3AOX | VAL | 1293 |
| 3AOX | LYS | 1294 |
| 3AOX | TRP | 1295 |
| 3AOX | MET | 1296 |
| 3AOX | PRO | 1297 |
| 3AOX | PRO | 1298 |
| 3AOX | GLU | 1299 |
| 3AOX | ALA | 1300 |
| 3AOX | PHE | 1301 |
| 3AOX | MET | 1302 |
| 3AOX | GLU | 1303 |
| 3AOX | GLY | 1304 |
| 3AOX | ILE | 1305 |
| 3AOX | PHE | 1306 |
| 3AOX | THR | 1307 |
| 3AOX | SER | 1308 |
| 3AOX | LYS | 1309 |
| 3AOX | THR | 1310 |
| 3AOX | ASP | 1311 |
| 3AOX | THR | 1312 |
| 3AOX | TRP | 1313 |
| 3AOX | SER | 1314 |
| 3AOX | PHE | 1315 |
| 3AOX | GLY | 1316 |
| 3AOX | VAL | 1317 |
| 3AOX | LEU | 1318 |
| 3AOX | LEU | 1319 |
| 3AOX | TRP | 1320 |
| 3AOX | GLU | 1321 |
| 3AOX | ILE | 1322 |
| 3AOX | PHE | 1323 |
| 3AOX | SER | 1324 |
| 3AOX | LEU | 1325 |
| 3AOX | GLY | 1326 |
| 3AOX | TYR | 1327 |
| 3AOX | MET | 1328 |
| 3AOX | PRO | 1329 |
| 3AOX | TYR | 1330 |
| 3AOX | PRO | 1331 |
| 3AOX | SER | 1332 |
| 3AOX | LYS | 1333 |
| 3AOX | SER | 1334 |
| 3AOX | ASN | 1335 |
| 3AOX | GLN | 1336 |
| 3AOX | GLU | 1337 |
| 3AOX | VAL | 1338 |
| 3AOX | LEU | 1339 |
| 3AOX | GLU | 1340 |
| 3AOX | PHE | 1341 |
| 3AOX | VAL | 1342 |
| 3AOX | THR | 1343 |
| 3AOX | SER | 1344 |
| 3AOX | GLY | 1345 |
| 3AOX | GLY | 1346 |
| 3AOX | ARG | 1347 |
| 3AOX | MET | 1348 |
| 3AOX | ASP | 1349 |
| 3AOX | PRO | 1350 |
| 3AOX | PRO | 1351 |
| 3AOX | LYS | 1352 |
| 3AOX | ASN | 1353 |
| 3AOX | CYS | 1354 |
| 3AOX | PRO | 1355 |
| 3AOX | GLY | 1356 |
| 3AOX | PRO | 1357 |
| 3AOX | VAL | 1358 |
| 3AOX | TYR | 1359 |
| 3AOX | ARG | 1360 |
| 3AOX | ILE | 1361 |
| 3AOX | MET | 1362 |
| 3AOX | THR | 1363 |
| 3AOX | GLN | 1364 |
| 3AOX | CYS | 1365 |
| 3AOX | TRP | 1366 |
| 3AOX | GLN | 1367 |
| 3AOX | HIS | 1368 |
| 3AOX | GLN | 1369 |
| 3AOX | PRO | 1370 |
| 3AOX | GLU | 1371 |
| 3AOX | ASP | 1372 |
| 3AOX | ARG | 1373 |
| 3AOX | PRO | 1374 |
| 3AOX | ASN | 1375 |
| 3AOX | PHE | 1376 |
| 3AOX | ALA | 1377 |
| 3AOX | ILE | 1378 |
| 3AOX | ILE | 1379 |
| 3AOX | LEU | 1380 |
| 3AOX | GLU | 1381 |
| 3AOX | ARG | 1382 |
| 3AOX | ILE | 1383 |
| 3AOX | GLU | 1384 |
| 3AOX | TYR | 1385 |
| 3AOX | CYS | 1386 |
| 3AOX | THR | 1387 |
| 3AOX | GLN | 1388 |
| 3AOX | ASP | 1389 |
| 3AOX | PRO | 1390 |
| 3AOX | ASP | 1391 |
| 3AOX | VAL | 1392 |
| 3AOX | ILE | 1393 |
| 3AOX | ASN | 1394 |
| 3AOX | THR | 1395 |
| 3AOX | ALA | 1396 |
| 3AOX | LEU | 1397 |
| 3AOX | PRO | 1398 |
| 3AOX | ILE | 1399 |
| 3AOX | GLU | 1400 |
| 3AOX | TYR | 1401 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | GLN | 53 |
| 4CGB | GLY | 54 |
| 4CGB | ALA | 55 |
| 4CGB | ALA | 56 |
| 4CGB | LEU | 57 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | GLN | 53 |
| 4CGB | GLY | 54 |
| 4CGB | ALA | 55 |
| 4CGB | ALA | 56 |
| 4CGB | LEU | 57 |
| 4CGB | ARG | 58 |
| 4CGB | MET | 13 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | GLN | 53 |
| 4CGB | MET | 13 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | GLN | 53 |
| 4CGB | GLY | 54 |
| 4CGB | ALA | 55 |
| 4CGB | ALA | 56 |
| 4CGB | LEU | 57 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | MET | 13 |
| 4CGB | GLU | 14 |
| 4CGB | VAL | 15 |
| 4CGB | ASP | 16 |
| 4CGB | ASP | 17 |
| 4CGB | ARG | 18 |
| 4CGB | VAL | 19 |
| 4CGB | SER | 20 |
| 4CGB | ALA | 21 |
| 4CGB | LEU | 22 |
| 4CGB | GLU | 23 |
| 4CGB | GLN | 24 |
| 4CGB | ARG | 25 |
| 4CGB | LEU | 26 |
| 4CGB | GLN | 27 |
| 4CGB | LEU | 28 |
| 4CGB | GLN | 29 |
| 4CGB | GLU | 30 |
| 4CGB | ASP | 31 |
| 4CGB | GLU | 32 |
| 4CGB | LEU | 33 |
| 4CGB | ALA | 34 |
| 4CGB | VAL | 35 |
| 4CGB | LEU | 36 |
| 4CGB | LYS | 37 |
| 4CGB | ALA | 38 |
| 4CGB | ALA | 39 |
| 4CGB | LEU | 40 |
| 4CGB | ALA | 41 |
| 4CGB | ASP | 42 |
| 4CGB | ALA | 43 |
| 4CGB | LEU | 44 |
| 4CGB | ARG | 45 |
| 4CGB | ARG | 46 |
| 4CGB | LEU | 47 |
| 4CGB | ARG | 48 |
| 4CGB | ALA | 49 |
| 4CGB | CYS | 50 |
| 4CGB | GLU | 51 |
| 4CGB | GLU | 52 |
| 4CGB | GLN | 53 |
| 4CGB | GLY | 54 |
| 4CGB | ALA | 55 |
| 4CGB | ALA | 56 |
| 4CGB | LEU | 57 |
| 4CGC | GLU | 35 |
| 4CGC | GLN | 34 |
| 4CGC | GLU | 37 |
| 4CGC | THR | 39 |
| 4CGC | LEU | 41 |
| 4CGC | ASP | 36 |
| 4CGC | VAL | 40 |
| 4CI8 | LYS | 176 |
| 4CI8 | GLU | 177 |
| 4CI8 | PRO | 178 |
| 4CI8 | VAL | 179 |
| 4CI8 | PHE | 180 |
| 4CI8 | SER | 181 |
| 4CI8 | ALA | 182 |
| 4CI8 | GLU | 183 |
| 4CI8 | GLU | 184 |
| 4CI8 | GLY | 185 |
| 4CI8 | TYR | 186 |
| 4CI8 | VAL | 187 |
| 4CI8 | LYS | 188 |
| 4CI8 | MET | 189 |
| 4CI8 | PHE | 190 |
| 4CI8 | LEU | 191 |
| 4CI8 | ARG | 192 |
| 4CI8 | GLY | 193 |
| 4CI8 | ARG | 194 |
| 4CI8 | PRO | 195 |
| 4CI8 | VAL | 196 |
| 4CI8 | THR | 197 |
| 4CI8 | MET | 198 |
| 4CI8 | TYR | 199 |
| 4CI8 | MET | 200 |
| 4CI8 | PRO | 201 |
| 4CI8 | LYS | 202 |
| 4CI8 | ASP | 203 |
| 4CI8 | GLN | 204 |
| 4CI8 | VAL | 205 |
| 4CI8 | ASP | 206 |
| 4CI8 | SER | 207 |
| 4CI8 | TYR | 208 |
| 4CI8 | SER | 209 |
| 4CI8 | LEU | 210 |
| 4CI8 | GLU | 211 |
| 4CI8 | ALA | 212 |
| 4CI8 | LYS | 213 |
| 4CI8 | VAL | 214 |
| 4CI8 | GLU | 215 |
| 4CI8 | LEU | 216 |
| 4CI8 | PRO | 217 |
| 4CI8 | THR | 218 |
| 4CI8 | LYS | 219 |
| 4CI8 | ARG | 220 |
| 4CI8 | LEU | 221 |
| 4CI8 | LYS | 222 |
| 4CI8 | LEU | 223 |
| 4CI8 | GLU | 224 |
| 4CI8 | TRP | 225 |
| 4CI8 | VAL | 226 |
| 4CI8 | TYR | 227 |
| 4CI8 | GLY | 228 |
| 4CI8 | TYR | 229 |
| 4CI8 | ARG | 230 |
| 4CI8 | GLY | 231 |
| 4CI8 | ARG | 232 |
| 4CI8 | ASP | 233 |
| 4CI8 | CYS | 234 |
| 4CI8 | ARG | 235 |
| 4CI8 | ASN | 236 |
| 4CI8 | ASN | 237 |
| 4CI8 | LEU | 238 |
| 4CI8 | TYR | 239 |
| 4CI8 | LEU | 240 |
| 4CI8 | LEU | 241 |
| 4CI8 | PRO | 242 |
| 4CI8 | THR | 243 |
| 4CI8 | GLY | 244 |
| 4CI8 | GLU | 245 |
| 4CI8 | THR | 246 |
| 4CI8 | VAL | 247 |
| 4CI8 | TYR | 248 |
| 4CI8 | PHE | 249 |
| 4CI8 | ILE | 250 |
| 4CI8 | ALA | 251 |
| 4CI8 | SER | 252 |
| 4CI8 | VAL | 253 |
| 4CI8 | VAL | 254 |
| 4CI8 | VAL | 255 |
| 4CI8 | LEU | 256 |
| 4CI8 | TYR | 257 |
| 4CI8 | ASN | 258 |
| 4CI8 | VAL | 259 |
| 4CI8 | GLU | 260 |
| 4CI8 | GLU | 261 |
| 4CI8 | GLN | 262 |
| 4CI8 | LEU | 263 |
| 4CI8 | GLN | 264 |
| 4CI8 | ARG | 265 |
| 4CI8 | HIS | 266 |
| 4CI8 | TYR | 267 |
| 4CI8 | ALA | 268 |
| 4CI8 | GLY | 269 |
| 4CI8 | HIS | 270 |
| 4CI8 | ASN | 271 |
| 4CI8 | ASP | 272 |
| 4CI8 | ASP | 273 |
| 4CI8 | VAL | 274 |
| 4CI8 | LYS | 275 |
| 4CI8 | CYS | 276 |
| 4CI8 | LEU | 277 |
| 4CI8 | ALA | 278 |
| 4CI8 | VAL | 279 |
| 4CI8 | HIS | 280 |
| 4CI8 | PRO | 281 |
| 4CI8 | ASP | 282 |
| 4CI8 | ARG | 283 |
| 4CI8 | ILE | 284 |
| 4CI8 | THR | 285 |
| 4CI8 | ILE | 286 |
| 4CI8 | ALA | 287 |
| 4CI8 | THR | 288 |
| 4CI8 | GLY | 289 |
| 4CI8 | GLN | 290 |
| 4CI8 | VAL | 291 |
| 4CI8 | ALA | 292 |
| 4CI8 | GLY | 293 |
| 4CI8 | THR | 294 |
| 4CI8 | SER | 295 |
| 4CI8 | LYS | 296 |
| 4CI8 | ASP | 297 |
| 4CI8 | GLY | 298 |
| 4CI8 | LYS | 299 |
| 4CI8 | GLN | 300 |
| 4CI8 | LEU | 301 |
| 4CI8 | PRO | 302 |
| 4CI8 | PRO | 303 |
| 4CI8 | HIS | 304 |
| 4CI8 | VAL | 305 |
| 4CI8 | ARG | 306 |
| 4CI8 | ILE | 307 |
| 4CI8 | TRP | 308 |
| 4CI8 | ASP | 309 |
| 4CI8 | SER | 310 |
| 4CI8 | VAL | 311 |
| 4CI8 | THR | 312 |
| 4CI8 | LEU | 313 |
| 4CI8 | ASN | 314 |
| 4CI8 | THR | 315 |
| 4CI8 | LEU | 316 |
| 4CI8 | HIS | 317 |
| 4CI8 | VAL | 318 |
| 4CI8 | ILE | 319 |
| 4CI8 | GLY | 320 |
| 4CI8 | ILE | 321 |
| 4CI8 | GLY | 322 |
| 4CI8 | PHE | 323 |
| 4CI8 | PHE | 324 |
| 4CI8 | ASP | 325 |
| 4CI8 | ARG | 326 |
| 4CI8 | ALA | 327 |
| 4CI8 | VAL | 328 |
| 4CI8 | THR | 329 |
| 4CI8 | CYS | 330 |
| 4CI8 | ILE | 331 |
| 4CI8 | ALA | 332 |
| 4CI8 | PHE | 333 |
| 4CI8 | SER | 334 |
| 4CI8 | LYS | 335 |
| 4CI8 | SER | 336 |
| 4CI8 | ASN | 337 |
| 4CI8 | GLY | 338 |
| 4CI8 | GLY | 339 |
| 4CI8 | THR | 340 |
| 4CI8 | ASN | 341 |
| 4CI8 | LEU | 342 |
| 4CI8 | CYS | 343 |
| 4CI8 | ALA | 344 |
| 4CI8 | VAL | 345 |
| 4CI8 | ASP | 346 |
| 4CI8 | ASP | 347 |
| 4CI8 | SER | 348 |
| 4CI8 | ASN | 349 |
| 4CI8 | ASP | 350 |
| 4CI8 | HIS | 351 |
| 4CI8 | VAL | 352 |
| 4CI8 | LEU | 353 |
| 4CI8 | SER | 354 |
| 4CI8 | VAL | 355 |
| 4CI8 | TRP | 356 |
| 4CI8 | ASP | 357 |
| 4CI8 | TRP | 358 |
| 4CI8 | GLN | 359 |
| 4CI8 | LYS | 360 |
| 4CI8 | GLU | 361 |
| 4CI8 | GLU | 362 |
| 4CI8 | LYS | 363 |
| 4CI8 | LEU | 364 |
| 4CI8 | ALA | 365 |
| 4CI8 | ASP | 366 |
| 4CI8 | VAL | 367 |
| 4CI8 | LYS | 368 |
| 4CI8 | CYS | 369 |
| 4CI8 | SER | 370 |
| 4CI8 | ASN | 371 |
| 4CI8 | GLU | 372 |
| 4CI8 | ALA | 373 |
| 4CI8 | VAL | 374 |
| 4CI8 | PHE | 375 |
| 4CI8 | ALA | 376 |
| 4CI8 | ALA | 377 |
| 4CI8 | ASP | 378 |
| 4CI8 | PHE | 379 |
| 4CI8 | HIS | 380 |
| 4CI8 | PRO | 381 |
| 4CI8 | THR | 382 |
| 4CI8 | ASP | 383 |
| 4CI8 | THR | 384 |
| 4CI8 | ASN | 385 |
| 4CI8 | ILE | 386 |
| 4CI8 | ILE | 387 |
| 4CI8 | VAL | 388 |
| 4CI8 | THR | 389 |
| 4CI8 | CYS | 390 |
| 4CI8 | GLY | 391 |
| 4CI8 | LYS | 392 |
| 4CI8 | SER | 393 |
| 4CI8 | HIS | 394 |
| 4CI8 | LEU | 395 |
| 4CI8 | TYR | 396 |
| 4CI8 | PHE | 397 |
| 4CI8 | TRP | 398 |
| 4CI8 | THR | 399 |
| 4CI8 | LEU | 400 |
| 4CI8 | GLU | 401 |
| 4CI8 | GLY | 402 |
| 4CI8 | SER | 403 |
| 4CI8 | SER | 404 |
| 4CI8 | LEU | 405 |
| 4CI8 | ASN | 406 |
| 4CI8 | LYS | 407 |
| 4CI8 | LYS | 408 |
| 4CI8 | GLN | 409 |
| 4CI8 | GLY | 410 |
| 4CI8 | LEU | 411 |
| 4CI8 | PHE | 412 |
| 4CI8 | GLU | 413 |
| 4CI8 | LYS | 414 |
| 4CI8 | GLN | 415 |
| 4CI8 | GLU | 416 |
| 4CI8 | LYS | 417 |
| 4CI8 | PRO | 418 |
| 4CI8 | LYS | 419 |
| 4CI8 | PHE | 420 |
| 4CI8 | VAL | 421 |
| 4CI8 | LEU | 422 |
| 4CI8 | CYS | 423 |
| 4CI8 | VAL | 424 |
| 4CI8 | THR | 425 |
| 4CI8 | PHE | 426 |
| 4CI8 | SER | 427 |
| 4CI8 | GLU | 428 |
| 4CI8 | ASN | 429 |
| 4CI8 | GLY | 430 |
| 4CI8 | ASP | 431 |
| 4CI8 | THR | 432 |
| 4CI8 | ILE | 433 |
| 4CI8 | THR | 434 |
| 4CI8 | GLY | 435 |
| 4CI8 | ASP | 436 |
| 4CI8 | SER | 437 |
| 4CI8 | SER | 438 |
| 4CI8 | GLY | 439 |
| 4CI8 | ASN | 440 |
| 4CI8 | ILE | 441 |
| 4CI8 | LEU | 442 |
| 4CI8 | VAL | 443 |
| 4CI8 | TRP | 444 |
| 4CI8 | GLY | 445 |
| 4CI8 | LYS | 446 |
| 4CI8 | GLY | 447 |
| 4CI8 | THR | 448 |
| 4CI8 | ASN | 449 |
| 4CI8 | ARG | 450 |
| 4CI8 | ILE | 451 |
| 4CI8 | SER | 452 |
| 4CI8 | TYR | 453 |
| 4CI8 | ALA | 454 |
| 4CI8 | VAL | 455 |
| 4CI8 | GLN | 456 |
| 4CI8 | GLY | 457 |
| 4CI8 | ALA | 458 |
| 4CI8 | HIS | 459 |
| 4CI8 | GLU | 460 |
| 4CI8 | GLY | 461 |
| 4CI8 | GLY | 462 |
| 4CI8 | ILE | 463 |
| 4CI8 | PHE | 464 |
| 4CI8 | ALA | 465 |
| 4CI8 | LEU | 466 |
| 4CI8 | CYS | 467 |
| 4CI8 | MET | 468 |
| 4CI8 | LEU | 469 |
| 4CI8 | ARG | 470 |
| 4CI8 | ASP | 471 |
| 4CI8 | GLY | 472 |
| 4CI8 | THR | 473 |
| 4CI8 | LEU | 474 |
| 4CI8 | VAL | 475 |
| 4CI8 | SER | 476 |
| 4CI8 | GLY | 477 |
| 4CI8 | GLY | 478 |
| 4CI8 | GLY | 479 |
| 4CI8 | LYS | 480 |
| 4CI8 | ASP | 481 |
| 4CI8 | ARG | 482 |
| 4CI8 | LYS | 483 |
| 4CI8 | LEU | 484 |
| 4CI8 | ILE | 485 |
| 4CI8 | SER | 486 |
| 4CI8 | TRP | 487 |
| 4CI8 | SER | 488 |
| 4CI8 | GLY | 489 |
| 4CI8 | ASN | 490 |
| 4CI8 | TYR | 491 |
| 4CI8 | GLN | 492 |
| 4CI8 | LYS | 493 |
| 4CI8 | LEU | 494 |
| 4CI8 | ARG | 495 |
| 4CI8 | LYS | 496 |
| 4CI8 | THR | 497 |
| 4CI8 | GLU | 498 |
| 4CI8 | ILE | 499 |
| 4CI8 | PRO | 500 |
| 4CI8 | GLU | 501 |
| 4CI8 | GLN | 502 |
| 4CI8 | PHE | 503 |
| 4CI8 | GLY | 504 |
| 4CI8 | PRO | 505 |
| 4CI8 | ILE | 506 |
| 4CI8 | ARG | 507 |
| 4CI8 | THR | 508 |
| 4CI8 | VAL | 509 |
| 4CI8 | ALA | 510 |
| 4CI8 | GLU | 511 |
| 4CI8 | GLY | 512 |
| 4CI8 | LYS | 513 |
| 4CI8 | GLY | 514 |
| 4CI8 | ASP | 515 |
| 4CI8 | VAL | 516 |
| 4CI8 | ILE | 517 |
| 4CI8 | LEU | 518 |
| 4CI8 | ILE | 519 |
| 4CI8 | GLY | 520 |
| 4CI8 | THR | 521 |
| 4CI8 | THR | 522 |
| 4CI8 | ARG | 523 |
| 4CI8 | ASN | 524 |
| 4CI8 | PHE | 525 |
| 4CI8 | VAL | 526 |
| 4CI8 | LEU | 527 |
| 4CI8 | GLN | 528 |
| 4CI8 | GLY | 529 |
| 4CI8 | THR | 530 |
| 4CI8 | LEU | 531 |
| 4CI8 | SER | 532 |
| 4CI8 | GLY | 533 |
| 4CI8 | ASP | 534 |
| 4CI8 | PHE | 535 |
| 4CI8 | THR | 536 |
| 4CI8 | PRO | 537 |
| 4CI8 | ILE | 538 |
| 4CI8 | THR | 539 |
| 4CI8 | GLN | 540 |
| 4CI8 | GLY | 541 |
| 4CI8 | HIS | 542 |
| 4CI8 | THR | 543 |
| 4CI8 | ASP | 544 |
| 4CI8 | GLU | 545 |
| 4CI8 | LEU | 546 |
| 4CI8 | TRP | 547 |
| 4CI8 | GLY | 548 |
| 4CI8 | LEU | 549 |
| 4CI8 | ALA | 550 |
| 4CI8 | ILE | 551 |
| 4CI8 | HIS | 552 |
| 4CI8 | ALA | 553 |
| 4CI8 | SER | 554 |
| 4CI8 | LYS | 555 |
| 4CI8 | SER | 556 |
| 4CI8 | GLN | 557 |
| 4CI8 | PHE | 558 |
| 4CI8 | LEU | 559 |
| 4CI8 | THR | 560 |
| 4CI8 | CYS | 561 |
| 4CI8 | GLY | 562 |
| 4CI8 | HIS | 563 |
| 4CI8 | ASP | 564 |
| 4CI8 | LYS | 565 |
| 4CI8 | HIS | 566 |
| 4CI8 | ALA | 567 |
| 4CI8 | THR | 568 |
| 4CI8 | LEU | 569 |
| 4CI8 | TRP | 570 |
| 4CI8 | ASP | 571 |
| 4CI8 | ALA | 572 |
| 4CI8 | VAL | 573 |
| 4CI8 | GLY | 574 |
| 4CI8 | HIS | 575 |
| 4CI8 | ARG | 576 |
| 4CI8 | PRO | 577 |
| 4CI8 | VAL | 578 |
| 4CI8 | TRP | 579 |
| 4CI8 | ASP | 580 |
| 4CI8 | LYS | 581 |
| 4CI8 | ILE | 582 |
| 4CI8 | ILE | 583 |
| 4CI8 | GLU | 584 |
| 4CI8 | ASP | 585 |
| 4CI8 | PRO | 586 |
| 4CI8 | ALA | 587 |
| 4CI8 | GLN | 588 |
| 4CI8 | SER | 589 |
| 4CI8 | SER | 590 |
| 4CI8 | GLY | 591 |
| 4CI8 | PHE | 592 |
| 4CI8 | HIS | 593 |
| 4CI8 | PRO | 594 |
| 4CI8 | SER | 595 |
| 4CI8 | GLY | 596 |
| 4CI8 | SER | 597 |
| 4CI8 | VAL | 598 |
| 4CI8 | VAL | 599 |
| 4CI8 | ALA | 600 |
| 4CI8 | VAL | 601 |
| 4CI8 | GLY | 602 |
| 4CI8 | THR | 603 |
| 4CI8 | LEU | 604 |
| 4CI8 | THR | 605 |
| 4CI8 | GLY | 606 |
| 4CI8 | ARG | 607 |
| 4CI8 | TRP | 608 |
| 4CI8 | PHE | 609 |
| 4CI8 | VAL | 610 |
| 4CI8 | PHE | 611 |
| 4CI8 | ASP | 612 |
| 4CI8 | THR | 613 |
| 4CI8 | GLU | 614 |
| 4CI8 | THR | 615 |
| 4CI8 | LYS | 616 |
| 4CI8 | ASP | 617 |
| 4CI8 | LEU | 618 |
| 4CI8 | VAL | 619 |
| 4CI8 | THR | 620 |
| 4CI8 | VAL | 621 |
| 4CI8 | HIS | 622 |
| 4CI8 | THR | 623 |
| 4CI8 | ASP | 624 |
| 4CI8 | GLY | 625 |
| 4CI8 | ASN | 626 |
| 4CI8 | GLU | 627 |
| 4CI8 | GLN | 628 |
| 4CI8 | LEU | 629 |
| 4CI8 | SER | 630 |
| 4CI8 | VAL | 631 |
| 4CI8 | MET | 632 |
| 4CI8 | ARG | 633 |
| 4CI8 | TYR | 634 |
| 4CI8 | SER | 635 |
| 4CI8 | PRO | 636 |
| 4CI8 | ASP | 637 |
| 4CI8 | GLY | 638 |
| 4CI8 | ASN | 639 |
| 4CI8 | PHE | 640 |
| 4CI8 | LEU | 641 |
| 4CI8 | ALA | 642 |
| 4CI8 | ILE | 643 |
| 4CI8 | GLY | 644 |
| 4CI8 | SER | 645 |
| 4CI8 | HIS | 646 |
| 4CI8 | ASP | 647 |
| 4CI8 | ASN | 648 |
| 4CI8 | CYS | 649 |
| 4CI8 | ILE | 650 |
| 4CI8 | TYR | 651 |
| 4CI8 | ILE | 652 |
| 4CI8 | TYR | 653 |
| 4CI8 | GLY | 654 |
| 4CI8 | VAL | 655 |
| 4CI8 | SER | 656 |
| 4CI8 | ASP | 657 |
| 4CI8 | ASN | 658 |
| 4CI8 | GLY | 659 |
| 4CI8 | ARG | 660 |
| 4CI8 | LYS | 661 |
| 4CI8 | TYR | 662 |
| 4CI8 | THR | 663 |
| 4CI8 | ARG | 664 |
| 4CI8 | VAL | 665 |
| 4CI8 | GLY | 666 |
| 4CI8 | LYS | 667 |
| 4CI8 | CYS | 668 |
| 4CI8 | SER | 669 |
| 4CI8 | GLY | 670 |
| 4CI8 | HIS | 671 |
| 4CI8 | SER | 672 |
| 4CI8 | SER | 673 |
| 4CI8 | PHE | 674 |
| 4CI8 | ILE | 675 |
| 4CI8 | THR | 676 |
| 4CI8 | HIS | 677 |
| 4CI8 | LEU | 678 |
| 4CI8 | ASP | 679 |
| 4CI8 | TRP | 680 |
| 4CI8 | SER | 681 |
| 4CI8 | VAL | 682 |
| 4CI8 | ASN | 683 |
| 4CI8 | SER | 684 |
| 4CI8 | GLN | 685 |
| 4CI8 | PHE | 686 |
| 4CI8 | LEU | 687 |
| 4CI8 | VAL | 688 |
| 4CI8 | SER | 689 |
| 4CI8 | ASN | 690 |
| 4CI8 | SER | 691 |
| 4CI8 | GLY | 692 |
| 4CI8 | ASP | 693 |
| 4CI8 | TYR | 694 |
| 4CI8 | GLU | 695 |
| 4CI8 | ILE | 696 |
| 4CI8 | LEU | 697 |
| 4CI8 | TYR | 698 |
| 4CI8 | TRP | 699 |
| 4CI8 | VAL | 700 |
| 4CI8 | PRO | 701 |
| 4CI8 | SER | 702 |
| 4CI8 | ALA | 703 |
| 4CI8 | CYS | 704 |
| 4CI8 | LYS | 705 |
| 4CI8 | GLN | 706 |
| 4CI8 | VAL | 707 |
| 4CI8 | VAL | 708 |
| 4CI8 | SER | 709 |
| 4CI8 | VAL | 710 |
| 4CI8 | GLU | 711 |
| 4CI8 | THR | 712 |
| 4CI8 | THR | 713 |
| 4CI8 | ARG | 714 |
| 4CI8 | ASP | 715 |
| 4CI8 | ILE | 716 |
| 4CI8 | GLU | 717 |
| 4CI8 | TRP | 718 |
| 4CI8 | ALA | 719 |
| 4CI8 | THR | 720 |
| 4CI8 | TYR | 721 |
| 4CI8 | THR | 722 |
| 4CI8 | CYS | 723 |
| 4CI8 | THR | 724 |
| 4CI8 | LEU | 725 |
| 4CI8 | GLY | 726 |
| 4CI8 | PHE | 727 |
| 4CI8 | HIS | 728 |
| 4CI8 | VAL | 729 |
| 4CI8 | PHE | 730 |
| 4CI8 | GLY | 731 |
| 4CI8 | VAL | 732 |
| 4CI8 | TRP | 733 |
| 4CI8 | PRO | 734 |
| 4CI8 | GLU | 735 |
| 4CI8 | GLY | 736 |
| 4CI8 | SER | 737 |
| 4CI8 | ASP | 738 |
| 4CI8 | GLY | 739 |
| 4CI8 | THR | 740 |
| 4CI8 | ASP | 741 |
| 4CI8 | ILE | 742 |
| 4CI8 | ASN | 743 |
| 4CI8 | ALA | 744 |
| 4CI8 | VAL | 745 |
| 4CI8 | CYS | 746 |
| 4CI8 | ARG | 747 |
| 4CI8 | ALA | 748 |
| 4CI8 | HIS | 749 |
| 4CI8 | GLU | 750 |
| 4CI8 | LYS | 751 |
| 4CI8 | LYS | 752 |
| 4CI8 | LEU | 753 |
| 4CI8 | LEU | 754 |
| 4CI8 | SER | 755 |
| 4CI8 | THR | 756 |
| 4CI8 | GLY | 757 |
| 4CI8 | ASP | 758 |
| 4CI8 | ASP | 759 |
| 4CI8 | PHE | 760 |
| 4CI8 | GLY | 761 |
| 4CI8 | LYS | 762 |
| 4CI8 | VAL | 763 |
| 4CI8 | HIS | 764 |
| 4CI8 | LEU | 765 |
| 4CI8 | PHE | 766 |
| 4CI8 | SER | 767 |
| 4CI8 | TYR | 768 |
| 4CI8 | PRO | 769 |
| 4CI8 | CYS | 770 |
| 4CI8 | SER | 771 |
| 4CI8 | GLN | 772 |
| 4CI8 | PHE | 773 |
| 4CI8 | ARG | 774 |
| 4CI8 | ALA | 775 |
| 4CI8 | PRO | 776 |
| 4CI8 | SER | 777 |
| 4CI8 | HIS | 778 |
| 4CI8 | ILE | 779 |
| 4CI8 | TYR | 780 |
| 4CI8 | GLY | 781 |
| 4CI8 | GLY | 782 |
| 4CI8 | HIS | 783 |
| 4CI8 | SER | 784 |
| 4CI8 | SER | 785 |
| 4CI8 | HIS | 786 |
| 4CI8 | VAL | 787 |
| 4CI8 | THR | 788 |
| 4CI8 | ASN | 789 |
| 4CI8 | VAL | 790 |
| 4CI8 | ASP | 791 |
| 4CI8 | PHE | 792 |
| 4CI8 | LEU | 793 |
| 4CI8 | CYS | 794 |
| 4CI8 | GLU | 795 |
| 4CI8 | ASP | 796 |
| 4CI8 | SER | 797 |
| 4CI8 | HIS | 798 |
| 4CI8 | LEU | 799 |
| 4CI8 | ILE | 800 |
| 4CI8 | SER | 801 |
| 4CI8 | THR | 802 |
| 4CI8 | GLY | 803 |
| 4CI8 | GLY | 804 |
| 4CI8 | LYS | 805 |
| 4CI8 | ASP | 806 |
| 4CI8 | THR | 807 |
| 4CI8 | SER | 808 |
| 4CI8 | ILE | 809 |
| 4CI8 | MET | 810 |
| 4CI8 | GLN | 811 |
| 4CI8 | TRP | 812 |
| 4CI8 | ARG | 813 |
| 4CI8 | VAL | 814 |
| 4CI8 | ILE | 815 |
| 4CI8 | LYS | 176 |
| 4CI8 | GLU | 177 |
| 4CI8 | PRO | 178 |
| 4CI8 | VAL | 179 |
| 4CI8 | PHE | 180 |
| 4CI8 | SER | 181 |
| 4CI8 | ALA | 182 |
| 4CI8 | GLU | 183 |
| 4CI8 | GLU | 184 |
| 4CI8 | GLY | 185 |
| 4CI8 | TYR | 186 |
| 4CI8 | VAL | 187 |
| 4CI8 | LYS | 188 |
| 4CI8 | MET | 189 |
| 4CI8 | PHE | 190 |
| 4CI8 | LEU | 191 |
| 4CI8 | ARG | 192 |
| 4CI8 | GLY | 193 |
| 4CI8 | ARG | 194 |
| 4CI8 | PRO | 195 |
| 4CI8 | VAL | 196 |
| 4CI8 | THR | 197 |
| 4CI8 | MET | 198 |
| 4CI8 | TYR | 199 |
| 4CI8 | MET | 200 |
| 4CI8 | PRO | 201 |
| 4CI8 | LYS | 202 |
| 4CI8 | ASP | 203 |
| 4CI8 | GLN | 204 |
| 4CI8 | VAL | 205 |
| 4CI8 | ASP | 206 |
| 4CI8 | SER | 207 |
| 4CI8 | TYR | 208 |
| 4CI8 | SER | 209 |
| 4CI8 | LEU | 210 |
| 4CI8 | GLU | 211 |
| 4CI8 | ALA | 212 |
| 4CI8 | LYS | 213 |
| 4CI8 | VAL | 214 |
| 4CI8 | GLU | 215 |
| 4CI8 | LEU | 216 |
| 4CI8 | PRO | 217 |
| 4CI8 | THR | 218 |
| 4CI8 | LYS | 219 |
| 4CI8 | ARG | 220 |
| 4CI8 | LEU | 221 |
| 4CI8 | LYS | 222 |
| 4CI8 | LEU | 223 |
| 4CI8 | GLU | 224 |
| 4CI8 | TRP | 225 |
| 4CI8 | VAL | 226 |
| 4CI8 | TYR | 227 |
| 4CI8 | GLY | 228 |
| 4CI8 | TYR | 229 |
| 4CI8 | ARG | 230 |
| 4CI8 | GLY | 231 |
| 4CI8 | ARG | 232 |
| 4CI8 | ASP | 233 |
| 4CI8 | CYS | 234 |
| 4CI8 | ARG | 235 |
| 4CI8 | ASN | 236 |
| 4CI8 | ASN | 237 |
| 4CI8 | LEU | 238 |
| 4CI8 | TYR | 239 |
| 4CI8 | LEU | 240 |
| 4CI8 | LEU | 241 |
| 4CI8 | PRO | 242 |
| 4CI8 | THR | 243 |
| 4CI8 | GLY | 244 |
| 4CI8 | GLU | 245 |
| 4CI8 | THR | 246 |
| 4CI8 | VAL | 247 |
| 4CI8 | TYR | 248 |
| 4CI8 | PHE | 249 |
| 4CI8 | ILE | 250 |
| 4CI8 | ALA | 251 |
| 4CI8 | SER | 252 |
| 4CI8 | VAL | 253 |
| 4CI8 | VAL | 254 |
| 4CI8 | VAL | 255 |
| 4CI8 | LEU | 256 |
| 4CI8 | TYR | 257 |
| 4CI8 | ASN | 258 |
| 4CI8 | VAL | 259 |
| 4CI8 | GLU | 260 |
| 4CI8 | GLU | 261 |
| 4CI8 | GLN | 262 |
| 4CI8 | LEU | 263 |
| 4CI8 | GLN | 264 |
| 4CI8 | ARG | 265 |
| 4CI8 | HIS | 266 |
| 4CI8 | TYR | 267 |
| 4CI8 | ALA | 268 |
| 4CI8 | GLY | 269 |
| 4CI8 | HIS | 270 |
| 4CI8 | ASN | 271 |
| 4CI8 | ASP | 272 |
| 4CI8 | ASP | 273 |
| 4CI8 | VAL | 274 |
| 4CI8 | LYS | 275 |
| 4CI8 | CYS | 276 |
| 4CI8 | LEU | 277 |
| 4CI8 | ALA | 278 |
| 4CI8 | VAL | 279 |
| 4CI8 | HIS | 280 |
| 4CI8 | PRO | 281 |
| 4CI8 | ASP | 282 |
| 4CI8 | ARG | 283 |
| 4CI8 | ILE | 284 |
| 4CI8 | THR | 285 |
| 4CI8 | ILE | 286 |
| 4CI8 | ALA | 287 |
| 4CI8 | THR | 288 |
| 4CI8 | GLY | 289 |
| 4CI8 | GLN | 290 |
| 4CI8 | VAL | 291 |
| 4CI8 | ALA | 292 |
| 4CI8 | GLY | 293 |
| 4CI8 | THR | 294 |
| 4CI8 | SER | 295 |
| 4CI8 | LYS | 296 |
| 4CI8 | ASP | 297 |
| 4CI8 | GLY | 298 |
| 4CI8 | LYS | 299 |
| 4CI8 | GLN | 300 |
| 4CI8 | LEU | 301 |
| 4CI8 | PRO | 302 |
| 4CI8 | PRO | 303 |
| 4CI8 | HIS | 304 |
| 4CI8 | VAL | 305 |
| 4CI8 | ARG | 306 |
| 4CI8 | ILE | 307 |
| 4CI8 | TRP | 308 |
| 4CI8 | ASP | 309 |
| 4CI8 | SER | 310 |
| 4CI8 | VAL | 311 |
| 4CI8 | THR | 312 |
| 4CI8 | LEU | 313 |
| 4CI8 | ASN | 314 |
| 4CI8 | THR | 315 |
| 4CI8 | LEU | 316 |
| 4CI8 | HIS | 317 |
| 4CI8 | VAL | 318 |
| 4CI8 | ILE | 319 |
| 4CI8 | GLY | 320 |
| 4CI8 | ILE | 321 |
| 4CI8 | GLY | 322 |
| 4CI8 | PHE | 323 |
| 4CI8 | PHE | 324 |
| 4CI8 | ASP | 325 |
| 4CI8 | ARG | 326 |
| 4CI8 | ALA | 327 |
| 4CI8 | VAL | 328 |
| 4CI8 | THR | 329 |
| 4CI8 | CYS | 330 |
| 4CI8 | ILE | 331 |
| 4CI8 | ALA | 332 |
| 4CI8 | PHE | 333 |
| 4CI8 | SER | 334 |
| 4CI8 | LYS | 335 |
| 4CI8 | SER | 336 |
| 4CI8 | ASN | 337 |
| 4CI8 | GLY | 338 |
| 4CI8 | GLY | 339 |
| 4CI8 | THR | 340 |
| 4CI8 | ASN | 341 |
| 4CI8 | LEU | 342 |
| 4CI8 | CYS | 343 |
| 4CI8 | ALA | 344 |
| 4CI8 | VAL | 345 |
| 4CI8 | ASP | 346 |
| 4CI8 | ASP | 347 |
| 4CI8 | SER | 348 |
| 4CI8 | ASN | 349 |
| 4CI8 | ASP | 350 |
| 4CI8 | HIS | 351 |
| 4CI8 | VAL | 352 |
| 4CI8 | LEU | 353 |
| 4CI8 | SER | 354 |
| 4CI8 | VAL | 355 |
| 4CI8 | TRP | 356 |
| 4CI8 | ASP | 357 |
| 4CI8 | TRP | 358 |
| 4CI8 | GLN | 359 |
| 4CI8 | LYS | 360 |
| 4CI8 | GLU | 361 |
| 4CI8 | GLU | 362 |
| 4CI8 | LYS | 363 |
| 4CI8 | LEU | 364 |
| 4CI8 | ALA | 365 |
| 4CI8 | ASP | 366 |
| 4CI8 | VAL | 367 |
| 4CI8 | LYS | 368 |
| 4CI8 | CYS | 369 |
| 4CI8 | SER | 370 |
| 4CI8 | ASN | 371 |
| 4CI8 | GLU | 372 |
| 4CI8 | ALA | 373 |
| 4CI8 | VAL | 374 |
| 4CI8 | PHE | 375 |
| 4CI8 | ALA | 376 |
| 4CI8 | ALA | 377 |
| 4CI8 | ASP | 378 |
| 4CI8 | PHE | 379 |
| 4CI8 | HIS | 380 |
| 4CI8 | PRO | 381 |
| 4CI8 | THR | 382 |
| 4CI8 | ASP | 383 |
| 4CI8 | THR | 384 |
| 4CI8 | ASN | 385 |
| 4CI8 | ILE | 386 |
| 4CI8 | ILE | 387 |
| 4CI8 | VAL | 388 |
| 4CI8 | THR | 389 |
| 4CI8 | CYS | 390 |
| 4CI8 | GLY | 391 |
| 4CI8 | LYS | 392 |
| 4CI8 | SER | 393 |
| 4CI8 | HIS | 394 |
| 4CI8 | LEU | 395 |
| 4CI8 | TYR | 396 |
| 4CI8 | PHE | 397 |
| 4CI8 | TRP | 398 |
| 4CI8 | THR | 399 |
| 4CI8 | LEU | 400 |
| 4CI8 | GLU | 401 |
| 4CI8 | GLY | 402 |
| 4CI8 | SER | 403 |
| 4CI8 | SER | 404 |
| 4CI8 | LEU | 405 |
| 4CI8 | ASN | 406 |
| 4CI8 | LYS | 407 |
| 4CI8 | LYS | 408 |
| 4CI8 | GLN | 409 |
| 4CI8 | GLY | 410 |
| 4CI8 | LEU | 411 |
| 4CI8 | PHE | 412 |
| 4CI8 | GLU | 413 |
| 4CI8 | LYS | 414 |
| 4CI8 | GLN | 415 |
| 4CI8 | GLU | 416 |
| 4CI8 | LYS | 417 |
| 4CI8 | PRO | 418 |
| 4CI8 | LYS | 419 |
| 4CI8 | PHE | 420 |
| 4CI8 | VAL | 421 |
| 4CI8 | LEU | 422 |
| 4CI8 | CYS | 423 |
| 4CI8 | VAL | 424 |
| 4CI8 | THR | 425 |
| 4CI8 | PHE | 426 |
| 4CI8 | SER | 427 |
| 4CI8 | GLU | 428 |
| 4CI8 | ASN | 429 |
| 4CI8 | GLY | 430 |
| 4CI8 | ASP | 431 |
| 4CI8 | THR | 432 |
| 4CI8 | ILE | 433 |
| 4CI8 | THR | 434 |
| 4CI8 | GLY | 435 |
| 4CI8 | ASP | 436 |
| 4CI8 | SER | 437 |
| 4CI8 | SER | 438 |
| 4CI8 | GLY | 439 |
| 4CI8 | ASN | 440 |
| 4CI8 | ILE | 441 |
| 4CI8 | LEU | 442 |
| 4CI8 | VAL | 443 |
| 4CI8 | TRP | 444 |
| 4CI8 | GLY | 445 |
| 4CI8 | LYS | 446 |
| 4CI8 | GLY | 447 |
| 4CI8 | THR | 448 |
| 4CI8 | ASN | 449 |
| 4CI8 | ARG | 450 |
| 4CI8 | ILE | 451 |
| 4CI8 | SER | 452 |
| 4CI8 | TYR | 453 |
| 4CI8 | ALA | 454 |
| 4CI8 | VAL | 455 |
| 4CI8 | GLN | 456 |
| 4CI8 | GLY | 457 |
| 4CI8 | ALA | 458 |
| 4CI8 | HIS | 459 |
| 4CI8 | GLU | 460 |
| 4CI8 | GLY | 461 |
| 4CI8 | GLY | 462 |
| 4CI8 | ILE | 463 |
| 4CI8 | PHE | 464 |
| 4CI8 | ALA | 465 |
| 4CI8 | LEU | 466 |
| 4CI8 | CYS | 467 |
| 4CI8 | MET | 468 |
| 4CI8 | LEU | 469 |
| 4CI8 | ARG | 470 |
| 4CI8 | ASP | 471 |
| 4CI8 | GLY | 472 |
| 4CI8 | THR | 473 |
| 4CI8 | LEU | 474 |
| 4CI8 | VAL | 475 |
| 4CI8 | SER | 476 |
| 4CI8 | GLY | 477 |
| 4CI8 | GLY | 478 |
| 4CI8 | GLY | 479 |
| 4CI8 | LYS | 480 |
| 4CI8 | ASP | 481 |
| 4CI8 | ARG | 482 |
| 4CI8 | LYS | 483 |
| 4CI8 | LEU | 484 |
| 4CI8 | ILE | 485 |
| 4CI8 | SER | 486 |
| 4CI8 | TRP | 487 |
| 4CI8 | SER | 488 |
| 4CI8 | GLY | 489 |
| 4CI8 | ASN | 490 |
| 4CI8 | TYR | 491 |
| 4CI8 | GLN | 492 |
| 4CI8 | LYS | 493 |
| 4CI8 | LEU | 494 |
| 4CI8 | ARG | 495 |
| 4CI8 | LYS | 496 |
| 4CI8 | THR | 497 |
| 4CI8 | GLU | 498 |
| 4CI8 | ILE | 499 |
| 4CI8 | PRO | 500 |
| 4CI8 | GLU | 501 |
| 4CI8 | GLN | 502 |
| 4CI8 | PHE | 503 |
| 4CI8 | GLY | 504 |
| 4CI8 | PRO | 505 |
| 4CI8 | ILE | 506 |
| 4CI8 | ARG | 507 |
| 4CI8 | THR | 508 |
| 4CI8 | VAL | 509 |
| 4CI8 | ALA | 510 |
| 4CI8 | GLU | 511 |
| 4CI8 | GLY | 512 |
| 4CI8 | LYS | 513 |
| 4CI8 | GLY | 514 |
| 4CI8 | ASP | 515 |
| 4CI8 | VAL | 516 |
| 4CI8 | ILE | 517 |
| 4CI8 | LEU | 518 |
| 4CI8 | ILE | 519 |
| 4CI8 | GLY | 520 |
| 4CI8 | THR | 521 |
| 4CI8 | THR | 522 |
| 4CI8 | ARG | 523 |
| 4CI8 | ASN | 524 |
| 4CI8 | PHE | 525 |
| 4CI8 | VAL | 526 |
| 4CI8 | LEU | 527 |
| 4CI8 | GLN | 528 |
| 4CI8 | GLY | 529 |
| 4CI8 | THR | 530 |
| 4CI8 | LEU | 531 |
| 4CI8 | SER | 532 |
| 4CI8 | GLY | 533 |
| 4CI8 | ASP | 534 |
| 4CI8 | PHE | 535 |
| 4CI8 | THR | 536 |
| 4CI8 | PRO | 537 |
| 4CI8 | ILE | 538 |
| 4CI8 | THR | 539 |
| 4CI8 | GLN | 540 |
| 4CI8 | GLY | 541 |
| 4CI8 | HIS | 542 |
| 4CI8 | THR | 543 |
| 4CI8 | ASP | 544 |
| 4CI8 | GLU | 545 |
| 4CI8 | LEU | 546 |
| 4CI8 | TRP | 547 |
| 4CI8 | GLY | 548 |
| 4CI8 | LEU | 549 |
| 4CI8 | ALA | 550 |
| 4CI8 | ILE | 551 |
| 4CI8 | HIS | 552 |
| 4CI8 | ALA | 553 |
| 4CI8 | SER | 554 |
| 4CI8 | LYS | 555 |
| 4CI8 | SER | 556 |
| 4CI8 | GLN | 557 |
| 4CI8 | PHE | 558 |
| 4CI8 | LEU | 559 |
| 4CI8 | THR | 560 |
| 4CI8 | CYS | 561 |
| 4CI8 | GLY | 562 |
| 4CI8 | HIS | 563 |
| 4CI8 | ASP | 564 |
| 4CI8 | LYS | 565 |
| 4CI8 | HIS | 566 |
| 4CI8 | ALA | 567 |
| 4CI8 | THR | 568 |
| 4CI8 | LEU | 569 |
| 4CI8 | TRP | 570 |
| 4CI8 | ASP | 571 |
| 4CI8 | ALA | 572 |
| 4CI8 | VAL | 573 |
| 4CI8 | GLY | 574 |
| 4CI8 | HIS | 575 |
| 4CI8 | ARG | 576 |
| 4CI8 | PRO | 577 |
| 4CI8 | VAL | 578 |
| 4CI8 | TRP | 579 |
| 4CI8 | ASP | 580 |
| 4CI8 | LYS | 581 |
| 4CI8 | ILE | 582 |
| 4CI8 | ILE | 583 |
| 4CI8 | GLU | 584 |
| 4CI8 | ASP | 585 |
| 4CI8 | PRO | 586 |
| 4CI8 | ALA | 587 |
| 4CI8 | GLN | 588 |
| 4CI8 | SER | 589 |
| 4CI8 | SER | 590 |
| 4CI8 | GLY | 591 |
| 4CI8 | PHE | 592 |
| 4CI8 | HIS | 593 |
| 4CI8 | PRO | 594 |
| 4CI8 | SER | 595 |
| 4CI8 | GLY | 596 |
| 4CI8 | SER | 597 |
| 4CI8 | VAL | 598 |
| 4CI8 | VAL | 599 |
| 4CI8 | ALA | 600 |
| 4CI8 | VAL | 601 |
| 4CI8 | GLY | 602 |
| 4CI8 | THR | 603 |
| 4CI8 | LEU | 604 |
| 4CI8 | THR | 605 |
| 4CI8 | GLY | 606 |
| 4CI8 | ARG | 607 |
| 4CI8 | TRP | 608 |
| 4CI8 | PHE | 609 |
| 4CI8 | VAL | 610 |
| 4CI8 | PHE | 611 |
| 4CI8 | ASP | 612 |
| 4CI8 | THR | 613 |
| 4CI8 | GLU | 614 |
| 4CI8 | THR | 615 |
| 4CI8 | LYS | 616 |
| 4CI8 | ASP | 617 |
| 4CI8 | LEU | 618 |
| 4CI8 | VAL | 619 |
| 4CI8 | THR | 620 |
| 4CI8 | VAL | 621 |
| 4CI8 | HIS | 622 |
| 4CI8 | THR | 623 |
| 4CI8 | ASP | 624 |
| 4CI8 | GLY | 625 |
| 4CI8 | ASN | 626 |
| 4CI8 | GLU | 627 |
| 4CI8 | GLN | 628 |
| 4CI8 | LEU | 629 |
| 4CI8 | SER | 630 |
| 4CI8 | VAL | 631 |
| 4CI8 | MET | 632 |
| 4CI8 | ARG | 633 |
| 4CI8 | TYR | 634 |
| 4CI8 | SER | 635 |
| 4CI8 | PRO | 636 |
| 4CI8 | ASP | 637 |
| 4CI8 | GLY | 638 |
| 4CI8 | ASN | 639 |
| 4CI8 | PHE | 640 |
| 4CI8 | LEU | 641 |
| 4CI8 | ALA | 642 |
| 4CI8 | ILE | 643 |
| 4CI8 | GLY | 644 |
| 4CI8 | SER | 645 |
| 4CI8 | HIS | 646 |
| 4CI8 | ASP | 647 |
| 4CI8 | ASN | 648 |
| 4CI8 | CYS | 649 |
| 4CI8 | ILE | 650 |
| 4CI8 | TYR | 651 |
| 4CI8 | ILE | 652 |
| 4CI8 | TYR | 653 |
| 4CI8 | GLY | 654 |
| 4CI8 | VAL | 655 |
| 4CI8 | SER | 656 |
| 4CI8 | ASP | 657 |
| 4CI8 | ASN | 658 |
| 4CI8 | GLY | 659 |
| 4CI8 | ARG | 660 |
| 4CI8 | LYS | 661 |
| 4CI8 | TYR | 662 |
| 4CI8 | THR | 663 |
| 4CI8 | ARG | 664 |
| 4CI8 | VAL | 665 |
| 4CI8 | GLY | 666 |
| 4CI8 | LYS | 667 |
| 4CI8 | CYS | 668 |
| 4CI8 | SER | 669 |
| 4CI8 | GLY | 670 |
| 4CI8 | HIS | 671 |
| 4CI8 | SER | 672 |
| 4CI8 | SER | 673 |
| 4CI8 | PHE | 674 |
| 4CI8 | ILE | 675 |
| 4CI8 | THR | 676 |
| 4CI8 | HIS | 677 |
| 4CI8 | LEU | 678 |
| 4CI8 | ASP | 679 |
| 4CI8 | TRP | 680 |
| 4CI8 | SER | 681 |
| 4CI8 | VAL | 682 |
| 4CI8 | ASN | 683 |
| 4CI8 | SER | 684 |
| 4CI8 | GLN | 685 |
| 4CI8 | PHE | 686 |
| 4CI8 | LEU | 687 |
| 4CI8 | VAL | 688 |
| 4CI8 | SER | 689 |
| 4CI8 | ASN | 690 |
| 4CI8 | SER | 691 |
| 4CI8 | GLY | 692 |
| 4CI8 | ASP | 693 |
| 4CI8 | TYR | 694 |
| 4CI8 | GLU | 695 |
| 4CI8 | ILE | 696 |
| 4CI8 | LEU | 697 |
| 4CI8 | TYR | 698 |
| 4CI8 | TRP | 699 |
| 4CI8 | VAL | 700 |
| 4CI8 | PRO | 701 |
| 4CI8 | SER | 702 |
| 4CI8 | ALA | 703 |
| 4CI8 | CYS | 704 |
| 4CI8 | LYS | 705 |
| 4CI8 | GLN | 706 |
| 4CI8 | VAL | 707 |
| 4CI8 | VAL | 708 |
| 4CI8 | SER | 709 |
| 4CI8 | VAL | 710 |
| 4CI8 | GLU | 711 |
| 4CI8 | THR | 712 |
| 4CI8 | THR | 713 |
| 4CI8 | ARG | 714 |
| 4CI8 | ASP | 715 |
| 4CI8 | ILE | 716 |
| 4CI8 | GLU | 717 |
| 4CI8 | TRP | 718 |
| 4CI8 | ALA | 719 |
| 4CI8 | THR | 720 |
| 4CI8 | TYR | 721 |
| 4CI8 | THR | 722 |
| 4CI8 | CYS | 723 |
| 4CI8 | THR | 724 |
| 4CI8 | LEU | 725 |
| 4CI8 | GLY | 726 |
| 4CI8 | PHE | 727 |
| 4CI8 | HIS | 728 |
| 4CI8 | VAL | 729 |
| 4CI8 | PHE | 730 |
| 4CI8 | GLY | 731 |
| 4CI8 | VAL | 732 |
| 4CI8 | TRP | 733 |
| 4CI8 | PRO | 734 |
| 4CI8 | GLU | 735 |
| 4CI8 | GLY | 736 |
| 4CI8 | SER | 737 |
| 4CI8 | ASP | 738 |
| 4CI8 | GLY | 739 |
| 4CI8 | THR | 740 |
| 4CI8 | ASP | 741 |
| 4CI8 | ILE | 742 |
| 4CI8 | ASN | 743 |
| 4CI8 | ALA | 744 |
| 4CI8 | VAL | 745 |
| 4CI8 | CYS | 746 |
| 4CI8 | ARG | 747 |
| 4CI8 | ALA | 748 |
| 4CI8 | HIS | 749 |
| 4CI8 | GLU | 750 |
| 4CI8 | LYS | 751 |
| 4CI8 | LYS | 752 |
| 4CI8 | LEU | 753 |
| 4CI8 | LEU | 754 |
| 4CI8 | SER | 755 |
| 4CI8 | THR | 756 |
| 4CI8 | GLY | 757 |
| 4CI8 | ASP | 758 |
| 4CI8 | ASP | 759 |
| 4CI8 | PHE | 760 |
| 4CI8 | GLY | 761 |
| 4CI8 | LYS | 762 |
| 4CI8 | VAL | 763 |
| 4CI8 | HIS | 764 |
| 4CI8 | LEU | 765 |
| 4CI8 | PHE | 766 |
| 4CI8 | SER | 767 |
| 4CI8 | TYR | 768 |
| 4CI8 | PRO | 769 |
| 4CI8 | CYS | 770 |
| 4CI8 | SER | 771 |
| 4CI8 | GLN | 772 |
| 4CI8 | PHE | 773 |
| 4CI8 | ARG | 774 |
| 4CI8 | ALA | 775 |
| 4CI8 | PRO | 776 |
| 4CI8 | SER | 777 |
| 4CI8 | HIS | 778 |
| 4CI8 | ILE | 779 |
| 4CI8 | TYR | 780 |
| 4CI8 | GLY | 781 |
| 4CI8 | GLY | 782 |
| 4CI8 | HIS | 783 |
| 4CI8 | SER | 784 |
| 4CI8 | SER | 785 |
| 4CI8 | HIS | 786 |
| 4CI8 | VAL | 787 |
| 4CI8 | THR | 788 |
| 4CI8 | ASN | 789 |
| 4CI8 | VAL | 790 |
| 4CI8 | ASP | 791 |
| 4CI8 | PHE | 792 |
| 4CI8 | LEU | 793 |
| 4CI8 | CYS | 794 |
| 4CI8 | GLU | 795 |
| 4CI8 | ASP | 796 |
| 4CI8 | SER | 797 |
| 4CI8 | HIS | 798 |
| 4CI8 | LEU | 799 |
| 4CI8 | ILE | 800 |
| 4CI8 | SER | 801 |
| 4CI8 | THR | 802 |
| 4CI8 | GLY | 803 |
| 4CI8 | GLY | 804 |
| 4CI8 | LYS | 805 |
| 4CI8 | ASP | 806 |
| 4CI8 | THR | 807 |
| 4CI8 | SER | 808 |
| 4CI8 | ILE | 809 |
| 4CI8 | MET | 810 |
| 4CI8 | GLN | 811 |
| 4CI8 | TRP | 812 |
| 4CI8 | ARG | 813 |
| 4CI8 | VAL | 814 |
| 4CI8 | ILE | 815 |
| 6MX8 | PRO | 1094 |
| 6MX8 | ASN | 1095 |
| 6MX8 | TYR | 1096 |
| 6MX8 | CYS | 1097 |
| 6MX8 | PHE | 1098 |
| 6MX8 | ALA | 1099 |
| 6MX8 | GLY | 1100 |
| 6MX8 | LYS | 1101 |
| 6MX8 | THR | 1102 |
| 6MX8 | SER | 1103 |
| 6MX8 | SER | 1104 |
| 6MX8 | ILE | 1105 |
| 6MX8 | SER | 1106 |
| 6MX8 | ASP | 1107 |
| 6MX8 | LEU | 1108 |
| 6MX8 | LYS | 1109 |
| 6MX8 | GLU | 1110 |
| 6MX8 | VAL | 1111 |
| 6MX8 | PRO | 1112 |
| 6MX8 | ARG | 1113 |
| 6MX8 | LYS | 1114 |
| 6MX8 | ASN | 1115 |
| 6MX8 | ILE | 1116 |
| 6MX8 | THR | 1117 |
| 6MX8 | LEU | 1118 |
| 6MX8 | ILE | 1119 |
| 6MX8 | ARG | 1120 |
| 6MX8 | GLY | 1121 |
| 6MX8 | LEU | 1122 |
| 6MX8 | GLY | 1123 |
| 6MX8 | HIS | 1124 |
| 6MX8 | GLY | 1128 |
| 6MX8 | GLU | 1129 |
| 6MX8 | VAL | 1130 |
| 6MX8 | TYR | 1131 |
| 6MX8 | GLU | 1132 |
| 6MX8 | GLY | 1133 |
| 6MX8 | GLN | 1134 |
| 6MX8 | VAL | 1135 |
| 6MX8 | SER | 1136 |
| 6MX8 | PRO | 1144 |
| 6MX8 | LEU | 1145 |
| 6MX8 | GLN | 1146 |
| 6MX8 | VAL | 1147 |
| 6MX8 | ALA | 1148 |
| 6MX8 | VAL | 1149 |
| 6MX8 | LYS | 1150 |
| 6MX8 | THR | 1151 |
| 6MX8 | LEU | 1152 |
| 6MX8 | PRO | 1153 |
| 6MX8 | GLU | 1154 |
| 6MX8 | VAL | 1155 |
| 6MX8 | CYS | 1156 |
| 6MX8 | SER | 1157 |
| 6MX8 | GLU | 1158 |
| 6MX8 | GLN | 1159 |
| 6MX8 | ASP | 1160 |
| 6MX8 | GLU | 1161 |
| 6MX8 | LEU | 1162 |
| 6MX8 | ASP | 1163 |
| 6MX8 | PHE | 1164 |
| 6MX8 | LEU | 1165 |
| 6MX8 | MET | 1166 |
| 6MX8 | GLU | 1167 |
| 6MX8 | ALA | 1168 |
| 6MX8 | LEU | 1169 |
| 6MX8 | ILE | 1170 |
| 6MX8 | ILE | 1171 |
| 6MX8 | SER | 1172 |
| 6MX8 | LYS | 1173 |
| 6MX8 | PHE | 1174 |
| 6MX8 | ASN | 1175 |
| 6MX8 | HIS | 1176 |
| 6MX8 | GLN | 1177 |
| 6MX8 | ASN | 1178 |
| 6MX8 | ILE | 1179 |
| 6MX8 | VAL | 1180 |
| 6MX8 | ARG | 1181 |
| 6MX8 | CYS | 1182 |
| 6MX8 | ILE | 1183 |
| 6MX8 | GLY | 1184 |
| 6MX8 | VAL | 1185 |
| 6MX8 | SER | 1186 |
| 6MX8 | LEU | 1187 |
| 6MX8 | GLN | 1188 |
| 6MX8 | SER | 1189 |
| 6MX8 | LEU | 1190 |
| 6MX8 | PRO | 1191 |
| 6MX8 | ARG | 1192 |
| 6MX8 | PHE | 1193 |
| 6MX8 | ILE | 1194 |
| 6MX8 | LEU | 1195 |
| 6MX8 | LEU | 1196 |
| 6MX8 | GLU | 1197 |
| 6MX8 | LEU | 1198 |
| 6MX8 | MET | 1199 |
| 6MX8 | ALA | 1200 |
| 6MX8 | GLY | 1201 |
| 6MX8 | GLY | 1202 |
| 6MX8 | ASP | 1203 |
| 6MX8 | LEU | 1204 |
| 6MX8 | LYS | 1205 |
| 6MX8 | SER | 1206 |
| 6MX8 | PHE | 1207 |
| 6MX8 | LEU | 1208 |
| 6MX8 | ARG | 1209 |
| 6MX8 | GLU | 1210 |
| 6MX8 | THR | 1211 |
| 6MX8 | ARG | 1212 |
| 6MX8 | PRO | 1213 |
| 6MX8 | ARG | 1214 |
| 6MX8 | PRO | 1215 |
| 6MX8 | PRO | 1218 |
| 6MX8 | SER | 1219 |
| 6MX8 | SER | 1220 |
| 6MX8 | LEU | 1221 |
| 6MX8 | ALA | 1222 |
| 6MX8 | MET | 1223 |
| 6MX8 | LEU | 1224 |
| 6MX8 | ASP | 1225 |
| 6MX8 | LEU | 1226 |
| 6MX8 | LEU | 1227 |
| 6MX8 | HIS | 1228 |
| 6MX8 | VAL | 1229 |
| 6MX8 | ALA | 1230 |
| 6MX8 | ARG | 1231 |
| 6MX8 | ASP | 1232 |
| 6MX8 | ILE | 1233 |
| 6MX8 | ALA | 1234 |
| 6MX8 | CYS | 1235 |
| 6MX8 | GLY | 1236 |
| 6MX8 | CYS | 1237 |
| 6MX8 | GLN | 1238 |
| 6MX8 | TYR | 1239 |
| 6MX8 | LEU | 1240 |
| 6MX8 | GLU | 1241 |
| 6MX8 | GLU | 1242 |
| 6MX8 | ASN | 1243 |
| 6MX8 | HIS | 1244 |
| 6MX8 | PHE | 1245 |
| 6MX8 | ILE | 1246 |
| 6MX8 | HIS | 1247 |
| 6MX8 | ARG | 1248 |
| 6MX8 | ASP | 1249 |
| 6MX8 | ILE | 1250 |
| 6MX8 | ALA | 1251 |
| 6MX8 | ALA | 1252 |
| 6MX8 | ARG | 1253 |
| 6MX8 | ASN | 1254 |
| 6MX8 | CYS | 1255 |
| 6MX8 | LEU | 1256 |
| 6MX8 | LEU | 1257 |
| 6MX8 | THR | 1258 |
| 6MX8 | CYS | 1259 |
| 6MX8 | PRO | 1260 |
| 6MX8 | GLY | 1261 |
| 6MX8 | PRO | 1262 |
| 6MX8 | GLY | 1263 |
| 6MX8 | ARG | 1264 |
| 6MX8 | VAL | 1265 |
| 6MX8 | ALA | 1266 |
| 6MX8 | LYS | 1267 |
| 6MX8 | ILE | 1268 |
| 6MX8 | GLY | 1269 |
| 6MX8 | ASP | 1270 |
| 6MX8 | PHE | 1271 |
| 6MX8 | GLY | 1272 |
| 6MX8 | MET | 1273 |
| 6MX8 | ALA | 1274 |
| 6MX8 | CYS | 1288 |
| 6MX8 | ALA | 1289 |
| 6MX8 | MET | 1290 |
| 6MX8 | LEU | 1291 |
| 6MX8 | PRO | 1292 |
| 6MX8 | VAL | 1293 |
| 6MX8 | LYS | 1294 |
| 6MX8 | TRP | 1295 |
| 6MX8 | MET | 1296 |
| 6MX8 | PRO | 1297 |
| 6MX8 | PRO | 1298 |
| 6MX8 | GLU | 1299 |
| 6MX8 | ALA | 1300 |
| 6MX8 | PHE | 1301 |
| 6MX8 | MET | 1302 |
| 6MX8 | GLU | 1303 |
| 6MX8 | GLY | 1304 |
| 6MX8 | ILE | 1305 |
| 6MX8 | PHE | 1306 |
| 6MX8 | THR | 1307 |
| 6MX8 | SER | 1308 |
| 6MX8 | LYS | 1309 |
| 6MX8 | THR | 1310 |
| 6MX8 | ASP | 1311 |
| 6MX8 | THR | 1312 |
| 6MX8 | TRP | 1313 |
| 6MX8 | SER | 1314 |
| 6MX8 | PHE | 1315 |
| 6MX8 | GLY | 1316 |
| 6MX8 | VAL | 1317 |
| 6MX8 | LEU | 1318 |
| 6MX8 | LEU | 1319 |
| 6MX8 | TRP | 1320 |
| 6MX8 | GLU | 1321 |
| 6MX8 | ILE | 1322 |
| 6MX8 | PHE | 1323 |
| 6MX8 | SER | 1324 |
| 6MX8 | LEU | 1325 |
| 6MX8 | GLY | 1326 |
| 6MX8 | TYR | 1327 |
| 6MX8 | MET | 1328 |
| 6MX8 | PRO | 1329 |
| 6MX8 | TYR | 1330 |
| 6MX8 | PRO | 1331 |
| 6MX8 | SER | 1332 |
| 6MX8 | LYS | 1333 |
| 6MX8 | SER | 1334 |
| 6MX8 | ASN | 1335 |
| 6MX8 | GLN | 1336 |
| 6MX8 | GLU | 1337 |
| 6MX8 | VAL | 1338 |
| 6MX8 | LEU | 1339 |
| 6MX8 | GLU | 1340 |
| 6MX8 | PHE | 1341 |
| 6MX8 | VAL | 1342 |
| 6MX8 | THR | 1343 |
| 6MX8 | SER | 1344 |
| 6MX8 | GLY | 1345 |
| 6MX8 | GLY | 1346 |
| 6MX8 | ARG | 1347 |
| 6MX8 | MET | 1348 |
| 6MX8 | ASP | 1349 |
| 6MX8 | PRO | 1350 |
| 6MX8 | PRO | 1351 |
| 6MX8 | LYS | 1352 |
| 6MX8 | ASN | 1353 |
| 6MX8 | CYS | 1354 |
| 6MX8 | PRO | 1355 |
| 6MX8 | GLY | 1356 |
| 6MX8 | PRO | 1357 |
| 6MX8 | VAL | 1358 |
| 6MX8 | TYR | 1359 |
| 6MX8 | ARG | 1360 |
| 6MX8 | ILE | 1361 |
| 6MX8 | MET | 1362 |
| 6MX8 | THR | 1363 |
| 6MX8 | GLN | 1364 |
| 6MX8 | CYS | 1365 |
| 6MX8 | TRP | 1366 |
| 6MX8 | GLN | 1367 |
| 6MX8 | HIS | 1368 |
| 6MX8 | GLN | 1369 |
| 6MX8 | PRO | 1370 |
| 6MX8 | GLU | 1371 |
| 6MX8 | ASP | 1372 |
| 6MX8 | ARG | 1373 |
| 6MX8 | PRO | 1374 |
| 6MX8 | ASN | 1375 |
| 6MX8 | PHE | 1376 |
| 6MX8 | ALA | 1377 |
| 6MX8 | ILE | 1378 |
| 6MX8 | ILE | 1379 |
| 6MX8 | LEU | 1380 |
| 6MX8 | GLU | 1381 |
| 6MX8 | ARG | 1382 |
| 6MX8 | ILE | 1383 |
| 6MX8 | GLU | 1384 |
| 6MX8 | TYR | 1385 |
| 6MX8 | CYS | 1386 |
| 6MX8 | THR | 1387 |
| 6MX8 | GLN | 1388 |
| 6MX8 | ASP | 1389 |
| 6MX8 | PRO | 1390 |
| 6MX8 | ASP | 1391 |
| 6MX8 | VAL | 1392 |
| 6MX8 | ILE | 1393 |
| 6MX8 | ASN | 1394 |
| 6MX8 | THR | 1395 |
| 6MX8 | ALA | 1396 |
| 6MX8 | LEU | 1397 |
| 6MX8 | PRO | 1398 |
| 6MX8 | ILE | 1399 |
| 6MX8 | GLU | 1400 |
Top |
Ramachandran Plot of Kinase Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| 160_EML4_ALK_ramachandran.png |
 |
| TKFP_256_EML4_ALK_ramachandran.png |
 |
| TKFP_257_EML4_ALK_ramachandran.png |
 |
| TKFP_258_EML4_ALK_ramachandran.png |
 |
| TKFP_259_EML4_ALK_ramachandran.png |
 |
| TKFP_260_EML4_ALK_ramachandran.png |
 |
| TKFP_261_EML4_ALK_ramachandran.png |
 |
| TKFP_262_EML4_ALK_ramachandran.png |
 |
| TKFP_263_EML4_ALK_ramachandran.png |
 |
| TKFP_264_EML4_ALK_ramachandran.png |
 |
| TKFP_265_EML4_ALK_ramachandran.png |
 |
| TKFP_274_EML4_ALK_ramachandran.png |
 |
| TKFP_275_EML4_ALK_ramachandran.png |
 |
| TKFP_276_EML4_ALK_ramachandran.png |
 |
| TKFP_277_EML4_ALK_ramachandran.png |
 |
Top |
Virtual Screening Results |
| Distribution of the average docking score across all approved kinase inhibitors. Distribution of the number of occurrence across all approved kinase inhibitors. |
| 5'-kinase fusion protein case |
| 3'-kinase fusion protein case |
 |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. * The detailed information of individual kinase inhibitors are available in the download page. |
| Fusion gene name info | Drug | Docking score | Glide g score | Glide energy |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Sunitinib | -6.54606 | -6.55026 | -39.5554 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Cabozantinib | -6.37411 | -6.41911 | -51.707 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Cabozantinib | -6.37411 | -6.41911 | -51.707 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Pemigatinib | -6.37252 | -6.45522 | -44.1943 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Pemigatinib | -6.37252 | -6.45522 | -44.1943 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Pemigatinib | -6.37252 | -6.45522 | -44.1943 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Netarsudil | -6.1169400000000005 | -6.12804 | -42.9751 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Netarsudil | -6.1169400000000005 | -6.12804 | -42.9751 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Lapatinib | -5.97459 | -6.06339 | -60.575 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Lapatinib | -5.923690000000001 | -6.012490000000001 | -59.8752 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Lenvatinib | -5.8705099999999995 | -5.8705099999999995 | -46.318000000000005 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Lapatinib | -5.83789 | -7.006289999999999 | -62.8928 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Lapatinib | -5.83789 | -7.006289999999999 | -62.8928 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Ponatinib | -5.73854 | -5.94514 | -50.2547 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Ponatinib | -5.73854 | -5.94514 | -50.2547 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Ponatinib | -5.73854 | -5.94514 | -50.2547 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Encorafenib | -5.66945 | -6.05795 | -48.8445 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Pexidartinib | -5.6675 | -6.3683 | -36.9237 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Pexidartinib | -5.6675 | -6.3683 | -36.9237 |
| 160_EML4_ALK-DOCK_HTVS_1-001 | Acalabrutinib | -5.62648 | -5.64058 | -46.6725 |
Top |
Kinase-Substrate Information of EML4_ALK |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| ALK | Q9UM73 | human | ALK | Q9UM73 | Y1604 | tAPGAGHyEDTILkS | |
| ALK | Q9UM73 | human | ELP3 | Q9H9T3 | Y202 | GHtSNNIyEAVkySE | Radical_SAM |
| ALK | Q9UM73 | human | ALK | Q9UM73 | Y1278 | FGMARDIyRAsyyRK | PK_Tyr_Ser-Thr |
| ALK | Q9UM73 | human | CDK9 | P50750 | Y19 | FCDEVSkyEkLAkIG | |
| ALK | Q9UM73 | human | SFPQ | P23246 | Y293 | RRPGEktyTQRCRLF | |
| ALK | Q9UM73 | human | ATIC | P31939 | Y104 | RVVACNLyPFVkTVA | MGS |
| ALK | Q9UM73 | human | SRCIN1 | Q9C0H9 | Y396 | LVKGEGLyADPyGLL | |
| ALK | Q9UM73 | human | STAT3 | P40763 | Y705 | DPGsAAPyLktKFIC | |
| ALK | Q9UM73 | human | PTPN11 | Q06124 | Y580 | REDsARVyENVGLMQ | |
| ALK | Q9UM73 | human | PBK | Q96KB5 | Y74 | NPICNDHyRsVyQkR | Pkinase |
| ALK | Q9UM73 | human | VASP | P50552 | Y39 | AFSRVQIyHNPtANs | WH1 |
| ALK | Q9UM73 | human | PTPN11 | Q06124 | Y542 | sKRkGHEytNIKysL | |
| ALK | Q9UM73 | human | GRB2 | P62993 | Y160 | QVPQQPtyVQALFDF |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
Top |
Related Drugs to EML4_ALK |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| EML4 | ALK | Crizotinib | PubMed | 33157918 |
| Distribution of the number of studies mentioning EML4-ALK and kinase inhibitors the PubMed Abstract (04-01-2024) |
 |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
| EML1-ABL1 AND Crizotinib | EML4-ALK AND Crizotinib | 25874286 | 2022-03-17 | 10.1002/9781119671404.ch6 | "In vivo ""editing'' of cellular genome: one more step toward animals models mimicking tumorigenesis" |
| EML4-ALK AND Imatinib | EML4-ALK AND Vemurafenib | 22690483 | None | 10.1007/978-3-540-29734-5_31 | Will targeted therapies replace chemotherapy? |
| EML4-ALK AND Imatinib | SLC34A2-ROS1 AND Crizotinib | 22617245 | 2012-7 | 10.1097/jto.0b013e3182570919 | Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. |
| EML4-ALK AND Imatinib | 20954322 | 2020-02-07 | 10.32388/2ofwek | Cytoplasmic kinase inhibitors | |
| EML4-ALK AND Gefitinib | STRN-ALK AND Osimertinib | 34654390 | 2021-10-15 | 10.1186/s12885-021-08824-2 | Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. |
| EML4-ALK AND Gefitinib | 28373815 | 1905-07-08 | 10.5114/wo.2016.64593 | Systemic treatment of non-small cell lung cancer brain metastases. | |
| EML4-ALK AND Gefitinib | 24649213 | 2013-03-29 | 10.3892/mco.2013.100 | Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. | |
| EML4-ALK AND Gefitinib | EML4-ALK AND Erlotinib | 22620005 | 1905-07-03 | 10.1272/jnms.78.46 | Diagnostic and therapeutic biomarkers for lung cancer patients |
| EML4-ALK AND Gefitinib | EML4-ALK AND Erlotinib | 20954328 | 2018-10-15 | 10.1272/manms.14.177 | Molecular targeted therapy in lung cancer |
| EML4-ALK AND Erlotinib | 24781527 | 2014-04-29 | 10.1038/clpt.2014.93 | Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. | |
| EML4-ALK AND Erlotinib | EML4-ALK AND Crizotinib | 23227588 | 2014-07-01 | 10.14800/rci.152 | Personalized treatment in non-small cell lung cancer |
| EML4-ALK AND Erlotinib | EML4-ALK AND Afatinib | 22085575 | None | 10.1007/springerreference_178485 | New 'targeted therapy' for lung cancer |
| EML4-ALK AND Sorafenib | 26237499 | 2015-10 | 10.1097/cad.0000000000000277 | A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation. | |
| EML4-ALK AND Lapatinib | EML4-ALK AND Tivozanib | 25489176 | 2014-10-30 | 10.6026/97320630010658 | Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer. |
| EML4-ALK AND Crizotinib | 37950305 | 2023-11-10 | 10.1186/s13019-023-02427-7 | Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report. | |
| EML4-ALK AND Crizotinib | 36927974 | 2023-11-01 | 10.2169/internalmedicine.1164-22 | Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene. | |
| EML4-ALK AND Crizotinib | SEC31A-ALK AND Crizotinib | 36730620 | 2022-11-16 | 10.1097/cad.0000000000001408 | First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. |
| EML4-ALK AND Crizotinib | EML4-ALK AND Lorlatinib | 36093526 | 2022-8 | 10.21037/tcr-21-2838 | Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report. |
| EML4-ALK AND Crizotinib | 35999455 | 2022-08-23 | 10.1038/s12276-022-00835-8 | Crizotinib attenuates cancer metastasis by inhibiting TGF? signaling in non-small cell lung cancer cells. | |
| EML4-ALK AND Crizotinib | 35822498 | 2022-07-13 | 10.1080/07391102.2022.2091658 | A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC. | |
| EML4-ALK AND Crizotinib | 35433411 | 2022-03-31 | 10.3389/fonc.2022.789941 | Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report. | |
| EML4-ALK AND Crizotinib | 34630126 | 2021-09-24 | 10.3389/fphar.2021.759267 | LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis. | |
| EML4-ALK AND Crizotinib | 34626839 | 2022-2 | 10.1016/j.jtho.2021.09.016 | Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC. | |
| EML4-ALK AND Crizotinib | 34552337 | 2021-9 | 10.2147/ott.s325443 | High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Brigatinib | 34537440 | 2021-12 | 10.1016/j.jtho.2021.07.035 | Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. |
| EML4-ALK AND Crizotinib | 34373943 | 2021-08-09 | 10.1007/s00432-021-03664-w | Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Lorlatinib | 34034462 | 2017-05-22 | 10.1007/s11864-017-0479-8 | A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors ?and Chemotherapy |
| EML4-ALK AND Crizotinib | 33896729 | 2021-11 | 10.1016/j.cllc.2021.03.012 | A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib. | |
| EML4-ALK AND Crizotinib | 33816312 | 2021-03-17 | 10.3389/fonc.2021.655856 | Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Lorlatinib | 33790576 | 2021-3 | 10.2147/ott.s293901 | Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. |
| EML4-ALK AND Crizotinib | 33470536 | 2021-01-20 | 10.1111/1759-7714.13825 | Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. | |
| EML4-ALK AND Crizotinib | 33466277 | 2021-01-05 | 10.3390/cancers13010144 | NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Osimertinib | 33381953 | 2022-12-30 | 10.3390/curroncol30010041 | Early Blood-based Liquid Biopsy in Patients with Treatment-na�ve Metastatic Adenocarcinoma of the Lung: A Case Series. |
| EML4-ALK AND Crizotinib | 33225619 | 2020-11-22 | 10.1111/1759-7714.13726 | Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway. | |
| EML4-ALK AND Crizotinib | 33203201 | 2022-12-01 | 10.3390/ijms232315056 | Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Alectinib | 32878782 | 2020-9 | 10.21873/anticanres.14497 | ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. |
| EML4-ALK AND Crizotinib | 32819126 | 2020-8 | 10.21037/apm-20-1025 | An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review. | |
| EML4-ALK AND Crizotinib | 32344689 | 2020-04-24 | 10.3390/cancers12041054 | ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation. | |
| EML4-ALK AND Crizotinib | 32112982 | 2020-6 | 10.1016/j.jtho.2020.02.007 | Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. | |
| EML4-ALK AND Crizotinib | 31757376 | 2019-12 | 10.1016/j.jtho.2019.07.021 | "Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib." | |
| EML4-ALK AND Crizotinib | 31608224 | 2019-09-23 | 10.3389/fonc.2019.00880 | "The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer." | |
| EML4-ALK AND Crizotinib | 31451138 | 2017-11 | 10.1093/annonc/mdx671.025 | Efficacy and Safety of Crizotinib in Advanced or Recurrent ?ALK-positive Non-small Cell Lung Cancer | |
| EML4-ALK AND Crizotinib | 31447007 | 2019-9 | 10.1016/j.lungcan.2019.07.017 | Clinical significance of ROS1 5' deletions in non-small cell lung cancer. | |
| EML4-ALK AND Crizotinib | 31388026 | 2019-08-06 | 10.1038/s41598-019-46825-1 | Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity. | |
| EML4-ALK AND Crizotinib | 31122560 | 2019-6 | 10.1016/j.jtho.2019.01.032 | "Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib." | |
| EML4-ALK AND Crizotinib | 31027700 | 2019-5 | 10.1016/j.lungcan.2019.03.018 | "Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer." | |
| EML4-ALK AND Crizotinib | 30895431 | 2019-03-20 | 10.1007/s11523-019-00631-x | Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. | |
| EML4-ALK AND Crizotinib | 30882666 | 2019-3 | 10.1097/md.0000000000014826 | ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Lorlatinib | 30791979 | 2019-4 | 10.1016/j.bbrc.2019.02.016 | miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. |
| EML4-ALK AND Crizotinib | 35117067 | 2018-1 | 10.21037/tcr.2018.11.35 | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. | |
| EML4-ALK AND Crizotinib | 30381078 | 2019-09-06 | 10.2174/1568009618666181031152140 | CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK. | |
| EML4-ALK AND Crizotinib | 30368411 | 2018-11 | 10.1016/j.jtho.2018.05.035 | Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Palbociclib | 30290287 | 2019-1 | 10.1016/j.tranon.2018.09.013 | MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. |
| EML4-ALK AND Crizotinib | 30069759 | 2019-09-21 | 10.1007/s40278-019-67928-1 | Crizotinib. | |
| EML4-ALK AND Crizotinib | 29951342 | 1905-07-10 | 10.20892/j.issn.2095-3941.2018.0003 | Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report. | |
| EML4-ALK AND Crizotinib | 29950868 | 2018-6 | 10.2147/ott.s165290 | lincROR influences the stemness and crizotinib resistance in EML-ALK(+) non-small-cell lung cancer cells. | |
| EML4-ALK AND Crizotinib | 29444468 | 2018-4 | 10.1016/j.ejphar.2018.02.012 | "A major component of vitamin E, ?-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK." | |
| EML4-ALK AND Crizotinib | 29304828 | 2018-01-05 | 10.1186/s13014-017-0947-0 | Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. | |
| EML4-ALK AND Crizotinib | 29290262 | 2018-1 | 10.1016/j.lungcan.2017.10.011 | GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors. | |
| EML4-ALK AND Crizotinib | 29284707 | 2018-03-14 | 10.1158/1078-0432.ccr-17-3001 | Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. | |
| EML4-ALK AND Crizotinib | STRN-ALK AND Crizotinib | 30225407 | 2017-7 | 10.1016/j.mayocpiqo.2017.04.003 | A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib. |
| EML4-ALK AND Crizotinib | 28077299 | 2017-3 | 10.1016/j.phrs.2017.01.007 | Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. | |
| EML4-ALK AND Crizotinib | 27783866 | 2016-12-30 | 10.1111/cas.13111 | Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. | |
| EML4-ALK AND Crizotinib | 27341790 | 2016-11 | 10.1016/j.cllc.2016.05.006 | Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. | |
| EML4-ALK AND Crizotinib | 27606884 | 2016-10-17 | 10.1111/crj.12550 | "Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report." | |
| EML4-ALK AND Crizotinib | 27663401 | 2016-10 | 10.1016/j.jtho.2016.07.008 | "A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK." | |
| EML4-ALK AND Crizotinib | 27637025 | 2016-09-16 | 10.1371/journal.pone.0160752 | "ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country." | |
| EML4-ALK AND Crizotinib | 27472693 | 2016-7 | 10.1097/md.0000000000004221 | Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report. | |
| EML4-ALK AND Crizotinib | 27458283 | 2016-10-01 | 10.1200/jco.2016.68.5891 | Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? | |
| EML4-ALK AND Crizotinib | 27245569 | 2016-05-31 | 10.1634/theoncologist.2015-0497 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. | |
| EML4-ALK AND Crizotinib | 27237027 | 2016-7 | 10.1016/j.lungcan.2016.04.013 | "TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling." | |
| EML4-ALK AND Crizotinib | 27045755 | 2016-04-05 | 10.1371/journal.pone.0153065 | Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. | |
| EML4-ALK AND Crizotinib | EML4-ALK AND Alectinib | 26992917 | 2016-3 | 10.1016/j.neo.2016.02.001 | Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. |
| EML4-ALK AND Crizotinib | EML4-ALK AND Ceritinib | 26775573 | 2020-04-30 | 10.5195/ijms.2020.446 | News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy) |
| EML4-ALK AND Crizotinib | EML4-ALK AND Alectinib | 26719536 | 2016-03-14 | 10.1158/0008-5472.can-15-1010 | Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. |
| EML4-ALK AND Crizotinib | 26666609 | 1905-07-07 | 10.2169/internalmedicine.54.4996 | Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma. | |
| EML4-ALK AND Crizotinib | 26454342 | 2016-5 | 10.1016/j.cllc.2015.09.002 | Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. | |
| EML4-ALK AND Crizotinib | 26352533 | 2015-11 | 10.1097/jto.0000000000000668 | EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. | |
| EML4-ALK AND Crizotinib | 26327925 | 2015-06-26 | 10.1177/1758834015590593 | Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. | |
| EML4-ALK AND Crizotinib | 26142544 | 2015-9 | 10.1016/j.jmoldx.2015.04.002 | Droplet Digital PCR for Absolute Quantification of�EML4-ALK Gene Rearrangement in Lung Adenocarcinoma. | |
| EML4-ALK AND Crizotinib | 26137041 | 1905-07-07 | 10.3892/ol.2015.3003 | Primary signet-ring cell carcinoma of the lung treated with crizotinib: A case report. | |
| EML4-ALK AND Crizotinib | 26134230 | 2015-7 | 10.1097/jto.0000000000000409 | Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib. | |
| EML4-ALK AND Crizotinib | 26107243 | 2015-06-26 | 10.7314/apjcp.2015.16.11.4797 | A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer. | |
| EML4-ALK AND Crizotinib | 26104888 | 2021-09-25 | 10.1186/s12885-021-08784-7 | Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro | |
| EML4-ALK AND Crizotinib | 26045865 | 2015-04-01 | 10.6004/jadpro.2015.6.2.7 | Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer. | |
| EML4-ALK AND Crizotinib | 26018277 | 2014-12-12 | 10.1371/journal.pone.0114008 | Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer | |
| EML4-ALK AND Crizotinib | 25929953 | 2015-04-30 | 10.1183/09031936.00236414 | Therapeutic management of ALK+ nonsmall cell lung cancer patients. | |
| EML4-ALK AND Crizotinib | SDC4-ROS1 AND Crizotinib | 25922291 | 2015-9 | 10.1016/j.cllc.2015.03.002 | "Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling." |
| EML4-ALK AND Crizotinib | 25806283 | 2015-03-18 | 10.1371/journal.pone.0117032 | "Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements." | |
| EML4-ALK AND Crizotinib | 25592111 | 2015-2 | 10.1016/j.radonc.2014.12.009 | Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. | |
| EML4-ALK AND Crizotinib | 25501361 | 2014-12-12 | 10.1371/journal.pone.0114008 | "Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients." | |
| EML4-ALK AND Crizotinib | 25408655 | 2014-09-09 | 10.1159/000367780 | A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib. | |
| EML4-ALK AND Crizotinib | 25247338 | 2014-12 | 10.1097/jto.0000000000000379 | NSCLC and HER2: between lights and shadows. | |
| EML4-ALK AND Crizotinib | 25101240 | 2014-07-21 | 10.3389/fonc.2014.00174 | A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. | |
| EML4-ALK AND Crizotinib | 24992173 | 2015-2 | 10.1097/pai.0000000000000025 | ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. | |
| EML4-ALK AND Crizotinib | 24756793 | 2021-6 | 10.1007/s40278-021-97587-z | Crizotinib. | |
| EML4-ALK AND Crizotinib | 24486291 | 2014-4 | 10.1016/j.leukres.2013.12.027 | Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. | |
| EML4-ALK AND Crizotinib | 24199682 | 2014-1 | 10.1016/j.lungcan.2013.09.019 | Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. | |
| EML4-ALK AND Crizotinib | 24102046 | 2013-10-01 | 10.1186/2193-1801-2-497 | Presence of anaplastic lymphoma kinase in inflammatory breast cancer. | |
| EML4-ALK AND Crizotinib | 24019783 | 2013-08-14 | 10.1159/000354756 | Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer. | |
| EML4-ALK AND Crizotinib | 23910397 | 2014-1 | 10.1016/j.rppnen.2013.06.004 | Lung cancer during pregnancy: an unusual case. | |
| EML4-ALK AND Crizotinib | 23785245 | 2013-6 | 10.2147/cmar.s32973 | Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. | |
| EML4-ALK AND Crizotinib | 23769348 | 2020-7 | 10.1016/j.lungcan.2020.04.010 | Clinical research of crizotinib in advanced non-small cell lung cancer | |
| EML4-ALK AND Crizotinib | 23750540 | 2013-06-11 | 10.3109/0284186x.2013.802838 | Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia. | |
| EML4-ALK AND Crizotinib | 23664446 | 2013-8 | 10.1016/j.lungcan.2013.03.016 | EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. | |
| EML4-ALK AND Crizotinib | 23576200 | 2020-07-27 | 10.1080/14656566.2020.1796971 | Crizotinib - molecular therapy for lung cancer | |
| EML4-ALK AND Crizotinib | 23561899 | 2012-05-20 | 10.1200/jco.2012.30.15_suppl.7598 | Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer | |
| EML4-ALK AND Crizotinib | 23536384 | 2013-03-27 | 10.1002/cncy.21286 | The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. | |
| EML4-ALK AND Crizotinib | 23443800 | 2013-05-01 | 10.1158/1535-7163.mct-12-0868 | ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. | |
| EML4-ALK AND Crizotinib | 23394083 | 2013-07-01 | 10.2174/13816128113199990343 | New molecular targets in the treatment of NSCLC. | |
| EML4-ALK AND Crizotinib | 23386065 | 2013-2 | 10.1345/aph.1r002 | Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. | |
| EML4-ALK AND Crizotinib | 23328551 | 2013-2 | 10.1097/jto.0b013e3182746772 | Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. | |
| EML4-ALK AND Crizotinib | 23325296 | 2013-01-17 | 10.1007/s11523-012-0250-9 | ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. | |
| EML4-ALK AND Crizotinib | 23301645 | 2021-01-31 | 10.1201/9781003159469-16 | "EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy" | |
| EML4-ALK AND Crizotinib | 28210128 | 2012-12 | 10.2147/lctt.s12959 | Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. | |
| EML4-ALK AND Crizotinib | 23052178 | 2012-7 | 10.1177/030089161209800421 | EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis. | |
| EML4-ALK AND Crizotinib | 22986231 | 2016-7 | 10.1016/j.lungcan.2016.04.006 | Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? | |
| EML4-ALK AND Crizotinib | 22594847 | 1905-07-06 | 10.4236/mc.2014.31002 | Crizotinib in the treatment of non-small-cell lung cancer. | |
| EML4-ALK AND Crizotinib | 22336170 | 2022-06-24 | 10.3892/ol.2022.13397 | Study of EML4-ALK fusion gene as a biomarker in non-small cell lung cancer | |
| EML4-ALK AND Crizotinib | 22311682 | 2012-02-05 | 10.1007/s11912-012-0213-4 | The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. | |
| EML4-ALK AND Crizotinib | 23788933 | 2013-9 | 10.1016/j.cllc.2013.04.006 | Crizotinib in the treatment of non-small-cell lung carcinoma. | |
| EML4-ALK AND Crizotinib | 22034911 | 2011-10-31 | 10.1111/j.1747-0285.2011.01239.x | Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. | |
| EML4-ALK AND Crizotinib | 21757253 | 2012-1 | 10.1016/j.lungcan.2011.05.027 | ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. | |
| EML4-ALK AND Crizotinib | 21504625 | 2011-04-20 | 10.1186/1756-8722-4-16 | "Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP." | |
| EML4-ALK AND Crizotinib | 21475126 | 2012-10 | 10.1016/s0923-7534(20)32177-3 | New targets in advanced NSCLC: EML4-ALK. | |
| EML4-ALK AND Crizotinib | 26412935 | 2013-05-01 | 10.1158/1535-7163.mct-12-0868 | Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. | |
| EML4-ALK AND Crizotinib | 21208134 | 2011-01-05 | 10.1517/14728222.2011.550880 | "Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703." | |
| EML4-ALK AND Vandetanib | EML4-ALK AND Nintedanib | 27250896 | 2015-06-20 | 10.6000/1927-7229.2015.04.03.1 | Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer. |
| EML4-ALK AND Afatinib | 33935502 | 2021-4 | 10.2147/ott.s294635 | EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. | |
| EML4-ALK AND Afatinib | 31795298 | 2019-11-28 | 10.3390/cells8121538 | Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. | |
| EML4-ALK AND Trametinib | 32245216 | 2020-03-21 | 10.3390/ijms21062167 | Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib. | |
| EML4-ALK AND Ceritinib | EML4-ALK AND Brigatinib | 36096442 | 2022-12 | 10.1016/j.jtho.2022.08.018 | Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). |
| EML4-ALK AND Ceritinib | EML4-ALK AND Osimertinib | 34326746 | 2021-07-08 | 10.1159/000516404 | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation. |
| EML4-ALK AND Ceritinib | EML4-ALK AND Alectinib | 34159737 | 2021-06-23 | 10.1111/1759-7714.14058 | A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4?years by switching to ceritinib. |
| EML4-ALK AND Ceritinib | 33907223 | 2021-04-27 | 10.1038/s41598-021-87966-6 | "ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells." | |
| EML4-ALK AND Ceritinib | EML4-ALK AND Lorlatinib | 33489815 | 2020-12 | 10.21037/tlcr-20-331 | How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). |
| EML4-ALK AND Ceritinib | 33362184 | 2018-06-15 | 10.1101/mcs.a002550 | Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L. | |
| EML4-ALK AND Ceritinib | 32340536 | 2020-04-27 | 10.1177/1078155220919172 | Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient. | |
| EML4-ALK AND Ceritinib | 32227409 | 2020-05-22 | 10.1111/cas.14397 | In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. | |
| EML4-ALK AND Ceritinib | 31943796 | 2020-01-13 | 10.1111/1759-7714.13299 | Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. | |
| EML4-ALK AND Ceritinib | 30075548 | 2018-8 | 10.1097/md.0000000000011646 | Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report. | |
| EML4-ALK AND Ceritinib | 26923554 | 2016-5 | 10.1016/j.canlet.2016.02.009 | Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer. | |
| EML4-ALK AND Ceritinib | EML4-ALK AND Brigatinib | 26654422 | 2016-01-04 | 10.1586/14737140.2016.1131612 | Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. |
| EML4-ALK AND Ceritinib | 26622190 | 2015-9 | 10.2147/pgpm.s71100 | Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. | |
| EML4-ALK AND Ceritinib | 26361725 | 2015-12 | 10.1016/j.phrs.2015.09.003 | Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). | |
| EML4-ALK AND Ceritinib | 25806325 | 2017-09-10 | 10.1097/01.cot.0000525224.59025.0c | Ceritinib as a promising therapy for ALK related diseases. | |
| EML4-ALK AND Alectinib | 38205204 | 2023-12 | 10.21037/tlcr-23-658 | Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study. | |
| EML4-ALK AND Alectinib | 38195077 | 2023-12 | 10.21037/cco-23-111 | Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report. | |
| EML4-ALK AND Alectinib | 37663243 | 2023-08-17 | 10.3389/fphar.2023.1140894 | Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy. | |
| EML4-ALK AND Alectinib | 36688904 | 2023-01-24 | 10.1097/cad.0000000000001507 | Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. | |
| EML4-ALK AND Alectinib | 36636411 | 2022-12 | 10.21037/tlcr-22-803 | Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort. | |
| EML4-ALK AND Alectinib | 36612200 | 2022-12-29 | 10.3390/cancers15010204 | Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). | |
| EML4-ALK AND Alectinib | 36072009 | 2022-08-17 | 10.3892/ol.2022.13463 | Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report. | |
| EML4-ALK AND Alectinib | 35616090 | 2022-05-26 | 10.1002/cam4.4834 | Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence. | |
| EML4-ALK AND Alectinib | 35070986 | 2022-01-05 | 10.3389/fonc.2021.782682 | "Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy." | |
| EML4-ALK AND Alectinib | 35042152 | 2022-2 | 10.1016/j.esmoop.2021.100333 | "Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer." | |
| EML4-ALK AND Alectinib | 34763318 | 2022-1 | 10.6004/jnccn.2021.7077 | "A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK." | |
| EML4-ALK AND Alectinib | 34763158 | 2021-12 | 10.1016/j.lungcan.2021.10.015 | "Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report." | |
| EML4-ALK AND Alectinib | 34391065 | 2021-10 | 10.1016/j.lungcan.2021.07.020 | Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. | |
| EML4-ALK AND Alectinib | 34079286 | 2021-5 | 10.2147/ott.s310756 | Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC. | |
| EML4-ALK AND Alectinib | 34064158 | 2021-05-21 | 10.3390/curroncol28030180 | Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report. | |
| EML4-ALK AND Alectinib | 33906872 | 2021-4 | 10.1136/bcr-2020-240295 | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib. | |
| EML4-ALK AND Alectinib | 33776709 | 2021-03-01 | 10.1159/000511069 | Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature. | |
| EML4-ALK AND Alectinib | 32850382 | 2020-07-31 | 10.3389/fonc.2020.01259 | Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. | |
| EML4-ALK AND Alectinib | EML4-ALK AND Osimertinib | 32620470 | 2020-11 | 10.1016/j.cllc.2020.05.016 | EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature. |
| EML4-ALK AND Alectinib | 32088605 | 2020-4 | 10.1016/j.lungcan.2020.02.006 | Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. | |
| EML4-ALK AND Alectinib | 31766077 | 2019-11-25 | 10.1111/1759-7714.13259 | Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. | |
| EML4-ALK AND Alectinib | 30902613 | 2019-7 | 10.1016/j.jtho.2019.03.007 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib�in�Untreated ALK-Positive Advanced Non-Small Cell�Lung Cancer in the Global Phase III ALEX Study. | |
| EML4-ALK AND Alectinib | 30662002 | 1905-07-10 | 10.2139/ssrn.3228884 | Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. | |
| EML4-ALK AND Alectinib | 30171175 | 2019-01-01 | 10.1158/1541-7786.mcr-18-0325 | Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. | |
| EML4-ALK AND Alectinib | 30133144 | 2018-08-21 | 10.1111/1759-7714.12834 | Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant. | |
| EML4-ALK AND Alectinib | 30069772 | 2019-1 | 10.1007/s40278-019-56637-0 | Alectinib. | |
| EML4-ALK AND Alectinib | 29808239 | 2018-05-28 | 10.1007/s11864-018-0553-x | Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. | |
| EML4-ALK AND Alectinib | 28101031 | 2016-12-08 | 10.1159/000453314 | Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer. | |
| EML4-ALK AND Alectinib | 27405684 | 2016-11 | 10.1016/j.cllc.2016.05.005 | Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). | |
| EML4-ALK AND Alectinib | 26682573 | 2016-01-01 | 10.1158/1535-7163.mct-15-0084 | Activation of EGFR Bypass Signaling by TGF? Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. | |
| EML4-ALK AND Alectinib | 26200283 | 2015-8 | 10.1097/jto.0000000000000575 | A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib. | |
| EML4-ALK AND Alectinib | 25876560 | 1905-07-07 | 10.1358/dot.2015.51.3.2294597 | Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. | |
| EML4-ALK AND Alectinib | HIP1-ALK AND Alectinib | 25393796 | 2014-12 | 10.1097/jto.0000000000000368 | Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. |
| EML4-ALK AND Alectinib | 25205428 | 2014-09-10 | 10.1007/s00280-014-2578-6 | Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. | |
| EML4-ALK AND Alectinib | 25144242 | 2014-11 | 10.1097/jto.0000000000000311 | A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. | |
| EML4-ALK AND Alectinib | 24952482 | 2014-06-03 | 10.18632/oncotarget.2055 | Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. | |
| EML4-ALK AND Alectinib | 24887559 | 2014-9 | 10.1016/j.canlet.2014.05.020 | Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. | |
| EML4-ALK AND Osimertinib | 36728908 | 2022-12-23 | 10.1097/cad.0000000000001489 | Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. | |
| EML4-ALK AND Osimertinib | 34590027 | 2021-6 | 10.1016/j.jtocrr.2021.100179 | EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report. | |
| EML4-ALK AND Osimertinib | 32622727 | 2020-11 | 10.1016/j.cllc.2020.05.009 | Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC. | |
| EML4-ALK AND Osimertinib | 29713646 | 1905-07-10 | 10.1155/2018/9010353 | Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients. | |
| EML4-ALK AND Brigatinib | 37647220 | None | 10.1021/acs.jmedchem.3c00722.s002 | Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase. | |
| EML4-ALK AND Brigatinib | 37434391 | 2023-07-11 | 10.1111/cas.15888 | Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. | |
| EML4-ALK AND Brigatinib | 36922348 | 2023-05-04 | 10.1002/cbic.202200766 | Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. | |
| EML4-ALK AND Brigatinib | 33380260 | 2020-12-30 | 10.1080/15384047.2020.1836947 | The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. | |
| EML4-ALK AND Brigatinib | 32547089 | 2021-3 | 10.1016/j.jtho.2021.01.1217 | Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement. | |
| EML4-ALK AND Brigatinib | 32179332 | 2020-5 | 10.1016/j.ejmech.2020.112190 | Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. | |
| EML4-ALK AND Brigatinib | 31305295 | 2019-8 | 10.1097/cad.0000000000000787 | Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. | |
| EML4-ALK AND Brigatinib | 31033499 | 2019-11 | 10.1097/cad.0000000000000800 | Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient. | |
| EML4-ALK AND Gilteritinib | 38377822 | 2024-4 | 10.1016/j.bioorg.2024.107204 | Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins. | |
| EML4-ALK AND Gilteritinib | 33627640 | 2021-02-24 | 10.1038/s41467-021-21396-w | Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. | |
| EML4-ALK AND Lorlatinib | 37934724 | 2023-10-30 | 10.12659/ajcr.942150 | Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report. | |
| EML4-ALK AND Lorlatinib | 37187318 | 2023-7 | 10.1016/j.critrevonc.2023.104019 | "From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC." | |
| EML4-ALK AND Lorlatinib | 36207130 | 2022-10-07 | 10.1101/mcs.a006234 | Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. | |
| EML4-ALK AND Lorlatinib | 35660971 | 2022-7 | 10.1016/j.lungcan.2022.05.012 | Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. | |
| EML4-ALK AND Lorlatinib | 34589977 | 2021-1 | 10.1016/j.jtocrr.2020.100116 | A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. | |
| EML4-ALK AND Lorlatinib | 29650534 | 2018-05-31 | 10.1158/2159-8290.cd-17-1256 | Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. |
Top |
Related Diseases to EML4_ALK |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| EML4 | ALK | Lung Adenocarcinoma | PubMed | 33157918 |
| EML4 | ALK | Lung Adenocarcinoma | MyCancerGenome | |
| EML4 | ALK | Non-Small Cell Lung Carcinoma | MyCancerGenome | |
| EML4 | ALK | Adenocarcinoma Of Unknown Primary | MyCancerGenome | |
| EML4 | ALK | Unknown | MyCancerGenome | |
| EML4 | ALK | Breast Invasive Ductal Carcinoma | MyCancerGenome |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| D004195 | Disease Models, Animal |
| D019468 | Disease Management |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D020022 | Genetic Predisposition to Disease |
| D018572 | Disease-Free Survival |
| D000208 | Acute Disease, Chronic Disease, Lung Diseases, Interstitial |
| D002908 | Acute Disease, Chronic Disease, Lung Diseases, Interstitial |
| D017563 | Acute Disease, Chronic Disease, Lung Diseases, Interstitial |
| D018450 | Disease Progression |
| D018450 | Disease Progression |
| D018572 | Disease-Free Survival |
| D017563 | Lung Diseases, Interstitial |
| D019468 | Disease Management, Disease Progression |
| D018450 | Disease Management, Disease Progression |
| D004195 | Disease Models, Animal |
| D018450 | Disease Progression |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | EML4 | C0007131 | Non-Small Cell Lung Carcinoma | 6 | CTD_human |
| Hgene | EML4 | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
| Hgene | EML4 | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CTD_human |
| Tgene | ALK | C0007131 | Non-Small Cell Lung Carcinoma | 28 | CGI;CTD_human |
| Tgene | ALK | C0027819 | Neuroblastoma | 13 | CGI;CTD_human;ORPHANET |
| Tgene | ALK | C0152013 | Adenocarcinoma of lung (disorder) | 8 | CGI;CTD_human |
| Tgene | ALK | C2751681 | NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 | 8 | CLINGEN;UNIPROT |
| Tgene | ALK | C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 6 | CGI;CTD_human |
| Tgene | ALK | C0334121 | Inflammatory Myofibroblastic Tumor | 4 | CGI;CTD_human;ORPHANET |
| Tgene | ALK | C0018199 | Granuloma, Plasma Cell | 3 | CTD_human |
| Tgene | ALK | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Tgene | ALK | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
| Tgene | ALK | C0238463 | Papillary thyroid carcinoma | 2 | ORPHANET |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
| EML4-ALK | Brigatinib | NCT04223596 | Active, not recruiting | Phase 2 | Lung Cancer | 33 | April 15, 2025 |
| EML4-ALK | Crizotinib | NCT03052608 | Active, not recruiting | Phase 3 | Carcinoma, Non-Small-Cell Lung | 296 | December 31, 2028 |
| EML4-ALK | Lorlatinib | NCT03052608 | Active, not recruiting | Phase 3 | Carcinoma, Non-Small-Cell Lung | 296 | December 31, 2028 |
| EML4-ALK | Ceritinib | NCT02292550 | Completed | Phase 1 | Non-small Cell Lung Cancer | 27 | September 26, 2018 |
| EML4-ALK | Crizotinib | NCT01300429 | Completed | Lung Cancer | 30 | January 5, 2021 | |
| EML4-ALK | Crizotinib | NCT00965731 | Completed | Phase 1 | Non-Small Cell Lung Cancer | 27 | January 2014 |
| EML4-ALK | Crizotinib | NCT00932451 | Completed | Phase 2 | Carcinoma, Non-Small-Cell Lung | 1069 | December 2015 |
| EML4-ALK | Crizotinib | NCT01154140 | Completed | Phase 3 | Non Squamous Lung Cancer | 343 | November 30, 2016 |
| EML4-ALK | Erlotinib | NCT00965731 | Completed | Phase 1 | Non-Small Cell Lung Cancer | 27 | January 2014 |
| EML4-ALK | Crizotinib | NCT01994057 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 1000 | December 2026 | |
| EML4-ALK | Erlotinib | NCT01994057 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 1000 | December 2026 | |
| EML4-ALK | Gefitinib | NCT01994057 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 1000 | December 2026 | |
| EML4-ALK | Osimertinib | NCT01994057 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 1000 | December 2026 | |
| EML4-ALK | Afatinib | NCT02762877 | Terminated | Non Small Cell Lung Carcinoma | 140 | June 19, 2019 | |
| EML4-ALK | Erlotinib | NCT02762877 | Terminated | Non Small Cell Lung Carcinoma | 140 | June 19, 2019 | |
| EML4-ALK | Gefitinib | NCT02762877 | Terminated | Non Small Cell Lung Carcinoma | 140 | June 19, 2019 | |
| EML4-ALK | Erlotinib | NCT01100840 | Unknown status | Non Small Cell Lung Cancer | |||
| EML4-ALK | Gefitinib | NCT01100840 | Unknown status | Non Small Cell Lung Cancer |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |